Benign neoplasm: Conjunctiva

CD2_BENIGN_CONJUNCTIVA

No definition available.

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps	FinnGen
Phenotype data	520210
1. Apply sex-specific rule None	520210
2. Check conditions None	520210
3. Check pre-conditions, main-only, mode, registry filters Registry filters: Hospital discharge: ICD-10 — D31.0& Hospital discharge: ICD-9 — 2243 Hospital discharge: ICD-8 — 22400 Cause of death: ICD-10 — D31.0& Cause of death: ICD-9 — 2243 Cause of death: ICD-8 — 22400 2 out of 7 registries used, show all original rules.	1168
4. Check minimum number of events None	1168
5. Include endpoints None	1168
6. Filter based on genotype QC (FinnGen only)	1168

Control definitions (FinnGen only)

Controls for this endpoint are individuals that are not cases.

Extra metadata

Level in the ICD hierarchy: 3
First used in FinnGen datafreeze: DF2
Parent code in ICD-10: D31
Name in latin: Neoplasma benignum conjunctivae

NAME	CD2_BENIGN_CONJUNCTIVA
CONTROL_EXCLUDE
CONTROL_PRECONDITIONS
CONTROL_CONDITIONS
SEX
INCLUDE
PRE_CONDITIONS
CONDITIONS
OUTPAT_ICD
OUTPAT_OPER
HD_MAINONLY
HD_ICD_10_ATC
HD_ICD_10	D310
HD_ICD_9	2243
HD_ICD_8	22400
HD_ICD_10_EXCL
HD_ICD_9_EXCL
HD_ICD_8_EXCL
COD_MAINONLY
COD_ICD_10	D310
COD_ICD_9	2243
COD_ICD_8	22400
COD_ICD_10_EXCL
COD_ICD_9_EXCL
COD_ICD_8_EXCL
OPER_NOM
OPER_HL
OPER_HP1
OPER_HP2
KELA_REIMB
KELA_REIMB_ICD
KELA_ATC_NEEDOTHER
KELA_ATC
KELA_VNRO_NEEDOTHER
KELA_VNRO
CANC_TOPO
CANC_TOPO_EXCL
CANC_MORPH
CANC_MORPH_EXCL
CANC_BEHAV

Similar endpoints

↥

List of similar endpoints to Benign neoplasm: Conjunctiva based on the number of shared cases.

Similar with more cases:

Similar with less cases:

Benign neoplasm: Conjunctiva

Case counts by codes

↥

FinnGen case counts by registry codes:

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

	All	Female	Male
Number of individuals
Whole population	9125	4799	4289
Only index persons	8425	4519	3906
Unadjusted period prevalence (%)
Whole population	0.13	0.14	0.12
Only index persons	0.16	0.17	0.15
Median age at first event (years)
Whole population	46.75	47.84	45.62
Only index persons	46.86	48.15	45.37

-FinnGen-

Key figures

	All	Female	Male
Number of individuals	1168	687	481
Unadjusted period prevalence (%)	0.23	0.23	0.21
Median age at first event (years)	53.42	50.89	57.03

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS (R11)

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log₁₀(p-value) ≥ 6.

Matched cohort

Matched cases
1037: Matched controls
10369

Code

Vocabulary

Description

Odds Ratio

-log₁₀(p)

N matched cases

N matched controls

D31.0

ICD-10 Finland

Benign neoplasm: Conjunctiva

4503599627370496.0

323.0

907

CFC00

NOMESCO Finland

Excision of lesion of conjunctiva

990.1

309.1

288

CFA20

NOMESCO Finland

Biopsy of conjunctiva

344.2

122.0

121

22400

ICD-8 Finland

Benign neoplasm of eye, Conjunctivae

+∞

97.4

XCK10

NOMESCO Finland

Photography of fundus of eye

5.0

61.5

219

523

CBB30

NOMESCO Finland

Excision of lesion of eyelid

10.9

57.6

114

116

D23.1

ICD-10 Finland

Benign neoplasm: Skin of eyelid, including canthus

9.1

51.8

113

137

CF2S4

NOMESCO Finland

Photography of conjunctiva

98.4

43.1

2243A

ICD-9 Finland

Benign neoplasm of eye, Conjunctiva

+∞

40.9

S01XA20

ATC

artificial tears and other indifferent preparations; ophthalmic

2.3

34.0

491

2936

CBA10

NOMESCO Finland

Biopsy of eyelid

15.4

30.3

S01CA01

ATC

dexamethasone and antiinfectives; ophthalmic (ophth., corticosteroids and antiinfectives in comb.)

2.2

29.4

408

2346

3401

FHL

Removal of local modification or taking a specimen in the operating room

+∞

28.2

Z01.0

ICD-10 Finland

Examination of eyes and vision

2.5

23.8

216

991

H00.1

ICD-10 Finland

Chalazion

5.2

22.9

149

H11.4

ICD-10 Finland

Other conjunctival vascular disorders and cysts

20.6

21.8

H11.1

ICD-10 Finland

Conjunctival degenerations and deposits

17.1

19.2

H04.10

ICD-10 Finland

Dry eye syndrome

2.7

17.8

133

543

C69.00

ICD-10 Finland

Malignant tumor of the conjunctiva without histology

86.4

15.6

ZXA00

NOMESCO Finland

Right side

1.9

15.3

297

1845

F29

ICPC

Eye symptom/complaint other

2.6

14.0

104

421

CBB00

NOMESCO Finland

Excision of chalazion

6.9

12.7

S01GX01

ATC

cromoglicic acid; ophthalmic

1.9

11.7

206

1224

WX002

NOMESCO Finland

Sedation and analgesia

1.8

11.4

211

1274

CD2S4

NOMESCO Finland

Photography of eye

12.0

11.4

H11.8

ICD-10 Finland

Other specified disorders of conjunctiva

20.3

11.1

D31.6

ICD-10 Finland

Benign neoplasm: Orbit, unspecified

43.8

10.9

H01.0

ICD-10 Finland

Blepharitis

2.7

10.8

276

XCW99

NOMESCO Finland

Other investigative procedure of eye

2.1

10.7

122

612

CAB00

NOMESCO Finland

Anterior orbitotomy with excision of lesion

111.1

10.4

H10.3

ICD-10 Finland

Acute conjunctivitis, unspecified

2.7

10.4

280

S18

ICPC

Laceration/cut

1.6

10.1

402

2989

CK2S4

NOMESCO Finland

Plain photography of ocular fundus

2.6

10.0

301

H11.9

ICD-10 Finland

Disorder of conjunctiva, unspecified

40.5

10.0

ZXA05

NOMESCO Finland

Left side

1.6

9.2

258

1753

WX110

NOMESCO Finland

Local anesthesy

1.5

9.1

670

5674

N17

ICPC

Vertigo/dizziness

2.0

9.0

117

618

CA1CG

NOMESCO Finland

Eye and orbita extensive MRI examination with high intensity magnet

10.8

8.8

A98

ICPC

Health maint/preventive medicine

2.2

8.8

982

9241

D31.3

ICD-10 Finland

Benign neoplasm: Choroid

4.6

8.7

R03AC02

ATC

salbutamol; inhalant

1.5

8.6

506

4061

TCW99

NOMESCO Finland

Other minor procedure in eye surgery

5.1

8.1

H02AB06

ATC

prednisolone; systemic

1.5

7.6

436

3451

CBB99

NOMESCO Finland

Other excision or destruction of lesion of eyelid

10.1

7.5

H11.0

ICD-10 Finland

Pterygium

7.2

7.5

CFD10

NOMESCO Finland

Repair of conjunctiva

80.6

7.4

D31.1

ICD-10 Finland

Benign neoplasm: Cornea

80.6

7.4

S21

ICPC

Skin texture symptom/complaint

1.8

7.3

119

681

H10.4

ICD-10 Finland

Chronic conjunctivitis

5.8

7.2

TQX10

NOMESCO Finland

Biopsy of skin and subcutaneous tissue

2.0

6.9

477

CA1CM

NOMESCO Finland

Eye and orbita extensive MRI examination with 3 Tesla magnet

13.9

6.9

TCC10

NOMESCO Finland

Probing of lacrimal canaliculus/duct

8.3

6.8

XCC00

NOMESCO Finland

Investigative irrigation of lacrimal passages

4.2

6.8

Z90.0

ICD-10 Finland

Acquired absence of part of head and neck

40.3

6.8

T15.1

ICD-10 Finland

Foreign body in conjunctival sac

4.7

6.7

H02.8

ICD-10 Finland

Other specified disorders of eyelid

12.3

6.6

WX408

NOMESCO Finland

General anesthesy, balanced

1.5

6.6

254

1842

A02BC02

ATC

pantoprazole; systemic

1.4

6.5

610

5234

EB1HA

NOMESCO Finland

Panorama tomography of teeth and jaws or similar X-ray examination

1.4

6.5

374

2941

GD1AA

NOMESCO Finland

Thorax X-ray examination

1.4

6.5

391

3098

UJD10

NOMESCO Finland

Esophagoscopy, gastroscopy and duodenoscopy

1.5

6.4

264

1937

XCX10

NOMESCO Finland

Other photography of eye

70.3

6.4

Z01.8

ICD-10 Finland

Other specified special examinations

1.6

6.3

196

1352

R10.4

ICD-10 Finland

Other and unspecified abdominal pain

1.4

6.2

319

2449

A06AC01

ATC

ispaghula (psylla seeds); oral

1.5

6.2

217

1536

ZXA10

NOMESCO Finland

Bilateral

1.6

6.2

170

1137

S82

ICPC

Naevus/mole

1.7

6.2

116

700

H33.0

ICD-10 Finland

Retinal detachment with retinal break

3.2

6.1

LabWAS

↥

N Cases

N Controls

-log₁₀(p)

cases

controls

cases

controls

unit

-log₁₀(p)

N cases

N controls

(40768804) Tissue Pathology biopsy report

535

3889

1.69

16.89

2.3

2.1

—

(3013115) Eosinophils [#/volume] in Blood

610

4973

1.47

9.56

7.2

5.9

0.19

e9/l

0.07

536

4386

(3015377) Calcium [Moles/volume] in Serum or Plasma

429

3288

1.48

9.06

3.3

3.4

2.36

2.35

mmol/l

0.50

369

2880

(3013650) Neutrophils [#/volume] in Blood by Automated count

666

5565

1.46

8.93

10.1

8.9

3.94

4.09

e9/l

1.06

585

4884

(3006315) Basophils [#/volume] in Blood

589

4811

1.45

8.89

6.8

5.6

0.04

e9/l

0.30

516

4178

(3001604) Monocytes [#/volume] in Blood

584

4791

1.44

8.44

6.8

5.6

0.59

0.58

e9/l

0.45

509

4151

(3035995) Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma

841

7423

1.47

7.96

8.4

7.5

75.96

78.42

u/l

1.11

793

6962

(3009201) Thyrotropin [Units/volume] in Serum or Plasma

973

8861

1.59

7.88

5.3

4.7

1.84

2.04

mu/l

0.78

893

8089

(3022096) Basophils/100 leukocytes in Blood

533

4370

1.40

7.38

6.9

5.8

0.69

0.67

0.36

501

4078

(3006504) Eosinophils/100 leukocytes in Blood

547

4509

1.40

7.31

6.9

5.8

2.82

0.00

513

4197

(3019198) Lymphocytes [#/volume] in Blood

589

4926

1.39

7.18

6.9

5.7

1.89

e9/l

0.00

520

4359

(3019069) Monocytes/100 leukocytes in Blood

548

4530

1.40

7.15

7.1

6.0

8.73

8.63

0.33

514

4243

(40764999) Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)

983

9045

1.55

6.83

15.9

13.1

80.53

80.91

ml/min/173m2

0.21

797

7441

(40771025) 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma

486

3967

1.39

6.71

2.4

2.3

82.32

76.69

nmol/l

3.78

428

3542

(3024561) Albumin [Mass/volume] in Serum or Plasma

502

4120

1.38

6.70

5.2

4.7

35.93

35.53

g/l

0.85

462

3822

(3018095) Leukocytes [#/volume] in Urine

425

3398

1.39

6.62

4.5

3.7

55.79

90.84

e6/l

1.13

299

2424

(3018010) Neutrophils/100 leukocytes in Blood

548

4573

1.37

6.55

6.6

5.7

57.32

57.36

0.03

511

4284

(3013721) Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma

395

3132

1.39

6.42

3.1

3.2

34.94

32.00

u/l

0.41

376

2985

(3006140) Bilirubin.total [Moles/volume] in Serum or Plasma

594

5034

1.37

6.39

6.0

6.2

11.92

11.17

umol/l

0.48

557

4771

(3010813) Leukocytes [#/volume] in Blood

1119

10690

2.11

6.38

25.0

20.9

6.71

e9/l

0.01

1089

10396

(40761511) CBC panel - Blood by Automated count

1065

10022

1.71

6.35

14.8

13.5

—

(3023103) Potassium [Moles/volume] in Serum or Plasma

1054

9896

1.67

6.29

19.2

16.5

3.96

3.97

mmol/l

0.43

1025

9621

(3024731) MCV [Entitic volume]

1118

10687

2.08

6.20

24.9

20.8

91.06

91.02

0.09

1100

10535

(3035941) MCH [Entitic mass]

1118

10688

2.08

6.18

24.8

20.8

30.26

30.31

0.39

1100

10534

(3002030) Lymphocytes/100 leukocytes in Blood

553

4650

1.36

6.17

7.0

5.9

27.77

27.74

0.02

515

4336

(3026361) Erythrocytes [#/volume] in Blood

1118

10689

2.07

6.16

24.9

20.9

4.49

4.48

e12/l

0.32

1086

10400

(36304419) Bacteria [Presence] in Urine

332

2571

1.41

6.15

4.1

3.1

—

(3000963) Hemoglobin [Mass/volume] in Blood

1118

10693

2.06

6.09

25.1

21.0

135.02

135.06

g/l

0.03

1099

10534

(3048773) Triglyceride [Moles/volume] in Serum or Plasma --fasting

980

9066

1.50

6.07

4.1

3.9

1.27

1.29

mmol/l

0.43

880

8288

(43054903) Holo-transcobalamin II [Moles/volume] in Serum

475

3909

1.36

6.05

2.2

2.0

96.65

94.85

pmol/l

0.34

239

2006

(3007461) Platelets [#/volume] in Blood

1117

10684

2.04

6.02

25.0

20.9

249.51

250.62

e9/l

0.22

1089

10420

(3030467) Casts [#/volume] in Urine by Automated count

338

2639

1.40

5.94

4.1

3.1

0.32

0.49

e6/l

0.85

251

2006

(3001308) Cholesterol in LDL [Moles/volume] in Serum or Plasma

1028

9619

1.57

5.92

5.3

4.9

2.72

2.75

mmol/l

0.42

946

8848

(3013707) Erythrocyte sedimentation rate by Westergren method

797

7119

1.38

5.91

4.9

4.1

11.01

12.32

mm/h

2.14

738

6562

(3020059) Calcium [Moles/volume] corrected for albumin in Serum or Plasma

241

1774

1.45

5.88

3.1

3.0

2.46

2.45

mmol/l

0.30

216

1559

(3019900) Cholesterol [Moles/volume] in Serum or Plasma

1013

9452

1.54

5.86

4.7

4.4

4.62

4.65

mmol/l

0.48

924

8755

(3019550) Sodium [Moles/volume] in Serum or Plasma

1049

9869

1.62

5.81

19.1

16.4

139.66

mmol/l

0.00

1023

9611

(3008486) Thyroxine (T4) free [Moles/volume] in Serum or Plasma

823

7406

1.38

5.71

4.3

4.0

14.83

14.76

pmol/l

0.36

743

6733

(3037467) Urinalysis macro (dipstick) panel - Urine

749

6643

1.36

5.69

5.2

4.4

—

(40768797) Stomach Pathology biopsy report

187

1318

1.50

5.67

1.3

1.2

—

(42870588) Differential panel, method unspecified - Blood

400

3235

1.36

5.59

6.7

5.6

—

(3002582) Erythrocytes [#/volume] in Urine

362

2892

1.36

5.45

4.1

3.2

17.50

88.56

e6/l

2.46

281

2251

(3023602) Cholesterol in HDL [Moles/volume] in Serum or Plasma

1005

9393

1.50

5.43

4.6

4.3

1.48

1.47

mmol/l

0.23

915

8644

(3020460) C reactive protein [Mass/volume] in Serum or Plasma

1025

9622

1.53

5.39

17.1

14.2

21.98

23.84

mg/l

1.08

813

7643

(3018418) pH of Serum or Plasma

358

2861

1.36

5.36

4.8

4.1

7.40

0.11

556

(3016431) Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma

559

4775

1.33

5.34

7.2

6.8

1.22

1.21

mmol/l

0.70

473

4022

(3031040) Bacteria [#/volume] in Urine by Automated count

722

6400

1.34

5.32

5.5

4.5

42.27

2876.68

e6/l

2.07

(3021347) Calcium.ionized [Moles/volume] in Serum or Plasma

516

4364

1.33

5.26

6.5

6.0

1.21

mmol/l

0.08

463

3946

(3006923) Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma

1074

10203

1.65

5.22

12.2

10.4

25.54

25.84

u/l

0.25

1041

9853

(3030306) Epithelial cells.non-squamous [#/volume] in Urine by Automated count

216

1591

1.44

5.21

3.2

2.8

0.75

1.05

e6/l

1.16

124

906

(3022250) Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction

149

1019

1.53

5.20

4.1

235.45

252.25

u/l

0.65

142

962

(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection

682

6026

1.32

4.97

3.1

3.0

—

(3026910) Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma

715

6361

1.32

4.95

3.3

3.1

46.07

49.56

u/l

0.49

662

5958

(3032080) INR in Blood by Coagulation assay

464

3903

1.31

4.78

11.2

9.5

1.31

1.23

inr

0.88

130

1143

(3007164) IgA [Mass/volume] in Serum or Plasma

247

1891

1.39

4.76

1.6

1.5

2.43

g/l

0.01

136

1160

(3000850) Epithelial cells [#/volume] in Urine

264

2046

1.38

4.72

3.5

2.6

3.63

6.09

e6/l

4.23

234

1804

(3001122) Ferritin [Mass/volume] in Serum or Plasma

496

4226

1.30

4.60

3.3

2.7

122.60

122.34

ug/l

0.01

460

3896

(3019800) Troponin T.cardiac [Mass/volume] in Serum or Plasma

435

3659

1.30

4.39

3.9

3.7

42.87

51.43

ng/l

0.19

288

2538

(3018251) Fasting glucose [Moles/volume] in Serum or Plasma

990

9314

1.41

4.32

4.9

4.5

5.92

5.94

mmol/l

0.20

902

8465

(3048689) Calprotectin [Mass/mass] in Stool

161

1166

1.44

4.23

2.1

2.2

222.17

128.16

ug/g

0.89

123

912

(46236098) ABO and Rh group [Type] in Blood by Confirmatory method

293

2343

1.33

4.23

2.3

—

(3029187) Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma

340

2791

1.31

4.06

2.8

3.0

1323.47

1335.67

ng/l

0.02

292

2383

(3000492) Spirometry study

128

899

1.48

3.95

1.5

—

(3007853) Bacteria identified in Skin by Aerobe culture

157

1147

1.43

3.94

1.8

1.6

—

(3002256) Pathology report gross observation

170

1264

1.40

3.86

1.4

1.3

—

(3027831) CD3-CD16+CD56+ (Natural killer) cells/100 cells in Blood

2.94

3.74

3.2

2.3

24.00

15.00

—

(21493690) Lymphocyte T-cell and B-cell and Natural killer subsets panel - Blood

2.94

3.74

3.2

2.3

—

(3021960) Folate [Moles/volume] in Serum or Plasma

281

2283

1.30

3.56

1.6

1.5

20.47

20.69

nmol/l

0.10

238

1948

(3044889) 12 lead EKG panel

740

6756

1.26

3.52

4.3

3.8

—

(3051714) Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma

267

2159

1.31

3.50

1.7

0.85

1.14

mg/l

2.27

189

1649

(3044640) Blood type and Crossmatch panel - Blood

366

3083

1.27

3.49

2.4

2.3

—

(36660697) Celiac disease serology panel - Serum

108

753

1.48

3.48

1.2

—

(3026493) Urate [Moles/volume] in Serum or Plasma

303

2498

1.29

3.43

2.8

2.7

7768.02

6696.30

umol/l

0.13

271

2165

(3022145) Colonoscopy Study observation

144

1063

1.40

3.42

1.2

1.3

—

(40760892) CBC W Ordered Manual Differential panel - Blood

264

2145

1.30

3.33

4.9

4.5

—

(3019309) Folate [Moles/volume] in Red Blood Cells

224

1782

1.32

3.30

2.0

1.7

1298.15

1190.62

nmol/l

0.50

165

1332

(3015399) Transferrin receptor.soluble [Mass/volume] in Serum or Plasma

297

2454

1.28

3.29

2.4

2.1

2.98

3.03

mg/l

0.12

247

2089

(3016771) Amylase [Enzymatic activity/volume] in Serum or Plasma

360

3052

1.26

3.21

2.8

2.5

60.66

56.43

u/l

0.29

332

2837

(3008230) Borrelia burgdorferi IgM Ab [Units/volume] in Serum

633

1.49

3.18

2.3

2.5

12.03

16.18

au/ml

—

(3011397) Hemoglobin [Presence] in Urine by Test strip

265

2167

1.29

3.17

4.3

3.7

—

(3005772) Bilirubin.conjugated [Moles/volume] in Serum or Plasma

146

1099

1.38

3.10

3.1

2.7

6.69

8.21

umol/l

0.69

128

956

(3013826) Glucose [Moles/volume] in Serum or Plasma

624

5635

1.23

3.09

5.1

4.9

6.60

6.71

mmol/l

0.65

581

5258

(3037522) Nuclear Ab [Titer] in Serum

167

1285

1.35

3.08

1.4

1.3

489.73

502.16

titre

0.04

278

(40758558) Short blood count panel - Blood

287

2385

1.27

3.01

7.4

6.6

—

(3000060) B lymphocytes [#/volume] in Blood

4.31

2.99

4.7

2.0

107.78

176.25

e6/l

—

(3019050) Tissue transglutaminase IgA Ab [Units/volume] in Serum

262

2160

1.27

2.93

1.3

1.92

1.59

u/ml

0.10

576

(3026782) Osmolality of Urine

236

1928

1.28

2.83

3.6

2.8

548.78

548.94

mosm/kgh2o

0.00

201

1658

(36031861) Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory system specimen by NAA with probe detection

562

1.47

2.72

1.6

1.7

—

(3009261) Glucose [Presence] in Urine by Test strip

534

4788

1.21

2.71

4.6

3.7

0.00

0.01

estimate

0.80

884

(3004410) Hemoglobin A1c/Hemoglobin.total in Blood

928

8799

1.27

2.70

6.3

5.7

39.35

39.91

mmol/mol

1.28

862

8148

(3002385) Erythrocyte distribution width [Ratio]

857

8056

1.24

2.68

21.4

17.2

13.73

13.68

0.30

848

7882

(3007220) Creatine kinase [Enzymatic activity/volume] in Serum or Plasma

340

2915

1.23

2.68

2.1

194.10

233.59

u/l

0.33

315

2749

(43534045) MCM6 gene c.-13910C>T and -13915T>G [Identifier] in Blood or Tissue by Molecular genetics method Nominal

481

1.51

2.68

1.1

1.0

—

(3021589) Normoblasts [#/volume] in Blood

478

4247

1.21

2.64

11.3

9.5

0.00

e9/l

0.82

387

3486

(3016417) Amylase.pancreatic [Enzymatic activity/volume] in Serum or Plasma

117

873

1.38

2.64

2.4

2.5

161.11

41.99

u/l

0.46

744

(3024135) Streptococcus.beta-hemolytic [Presence] in Throat by Organism specific culture

207

1680

1.28

2.61

1.5

—

(3035350) Ketones [Presence] in Urine by Test strip

525

4711

1.21

2.61

4.6

3.7

0.00

estimate

0.00

100

912

(3021879) Hepatitis B virus core Ab [Presence] in Serum

663

1.42

2.55

1.5

1.4

—

(42868414) European tick borne encephalitis virus IgM Ab [Presence] in Serum by Immunoassay

3.05

2.53

1.2

1.3

—

(3025130) Human papilloma virus identified in Specimen

108

2.06

2.52

1.7

—

(3029879) Epithelial cells.squamous [#/volume] in Urine by Automated count

186

1496

1.29

2.52

3.4

2.9

2.77

2.37

e6/l

0.21

820

(3017446) Testosterone [Moles/volume] in Serum or Plasma

632

1.42

2.49

2.3

2.2

12.17

12.91

nmol/l

0.34

560

(3021614) Rheumatoid factor [Units/volume] in Serum or Plasma

202

1647

1.27

2.46

1.3

31.74

33.35

iu/ml

0.06

533

(40763571) Iron/Transferrin [Ratio] in Serum or Plasma

160

1268

1.30

2.43

2.9

2.4

22.84

22.78

0.01

133

1079

(4024509)

2.19

2.41

1.4

1.5

—

(3026989) Triiodothyronine (T3) Free [Moles/volume] in Serum or Plasma

595

1.43

2.38

2.4

3.3

4.28

4.56

pmol/l

1.86

519

(3045683) HLA typing for celiac disease panel - Blood or Tissue

2.52

2.36

1.0

—

(3001784) Prostate Specific Ag Free/Prostate specific Ag.total in Serum or Plasma

275

2339

1.23

2.31

4.7

4.3

22.70

21.67

0.53

152

1096

(3005013) Prostate Specific Ag Free [Mass/volume] in Serum or Plasma

206

1697

1.26

2.30

3.3

3.0

0.86

0.78

ug/l

0.17

142

1114

(3017044) Thyrotropin receptor Ab [Units/volume] in Serum

254

1.64

2.30

1.4

1.8

3.04

5.14

iu/l

1.01

(3024980) IgG subclass 4 [Mass/volume] in Serum

141

1.86

2.29

2.4

1.7

0.48

0.82

g/l

1.49

108

(3021601) Nitrite [Presence] in Urine by Test strip

523

4732

1.19

2.28

5.8

5.0

0.00

estimate

0.50

103

919

(3004789) Transferrin [Mass/volume] in Serum or Plasma

168

1356

1.28

2.22

2.7

2.4

2.36

2.33

g/l

0.26

161

1259

(3005322) IgE [Units/volume] in Serum or Plasma

612

1.40

2.21

1.5

1.2

281.60

205.74

u/ml

0.37

556

(3025839) Triglyceride [Moles/volume] in Serum or Plasma

301

2596

1.21

2.19

1.8

1.7

1.36

1.37

mmol/l

0.10

259

2185

(3022948) Iron [Moles/volume] in Serum or Plasma

181

1477

1.27

2.19

2.7

2.4

13.13

13.07

umol/l

0.04

169

1371

(3016436) Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma

2.63

2.19

1.3

2.8

198.00

205.74

u/l

0.12

(3028026) IgM [Mass/volume] in Serum or Plasma

597

1.40

2.17

1.9

1.8

1.08

1.47

g/l

1.63

546

(21492711) Cytomegalovirus IgG Ab avidity [Presence] in Serum or Plasma by Immunoassay

2.31

2.15

1.2

—

(3021197) Magnesium Ionized [Moles/volume] in Serum or Plasma

2.72

2.10

3.1

2.5

—

(3006184) Hemoglobin [Mass/volume] in Capillary blood

214

1.66

2.08

2.3

2.2

129.80

128.96

g/l

0.07

164

(3023368) Bacteria identified in Blood by Culture

302

2618

1.21

2.08

4.8

4.2

—

(3028717) Thiamine [Mass/volume] in Blood

5.02

2.07

1.0

1.4

—

(3017143) Hepatitis C virus Ab [Presence] in Serum

131

1038

1.30

2.01

1.8

1.5

—

(3023419) Bacteria identified in Sputum by Culture

133

1.82

2.00

1.9

2.8

—

(3044938) Influenza virus A RNA [Presence] in Specimen by NAA with probe detection

191

1586

1.24

2.00

1.8

—

(3051552) Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection

685

1.36

1.99

1.7

1.6

—

(3003191) Choriogonadotropin (pregnancy test) [Presence] in Serum or Plasma

217

1.63

1.99

2.0

1.6

—

(3013603) Prostate specific Ag [Mass/volume] in Serum or Plasma

329

2897

1.19

1.90

5.5

4.9

5.16

2.86

ug/l

0.47

297

2588

(3012095) Magnesium [Moles/volume] in Serum or Plasma

185

1540

1.24

1.90

3.0

3.4

0.82

0.81

mmol/l

0.34

171

1437

(4035726)

109

850

1.31

1.89

1.4

—

(3003338) MCHC [Mass/volume]

853

8116

1.19

1.88

22.7

18.3

332.21

332.43

g/l

0.30

847

8062

(3013139) Helicobacter pylori Ag [Presence] in Stool

606

1.36

1.86

1.3

1.2

—

(3038288) Influenza virus B RNA [Presence] in Specimen by NAA with probe detection

138

1114

1.27

1.85

1.7

1.8

—

(46237023) Hepatitis B virus core and surface Ab and surface Ag panel - Serum

270

1.54

1.83

1.6

1.3

—

(3029937) Albumin [Presence] in Urine by Test strip

293

2561

1.19

1.83

5.8

4.1

0.00

0.01

estimate

1.08

103

892

(3009542) Hematocrit [Volume Fraction] of Blood

917

8789

1.20

1.83

19.5

15.2

39.54

39.78

0.34

691

6265

(3027945) Reticulocytes/100 erythrocytes in Blood

129

1035

1.28

1.82

2.1

2.6

1.73

1.81

0.38

112

921

(3013527) Hepatitis B virus core IgM Ab [Presence] in Serum

169

1.67

1.78

1.2

—

(3000991) Gas panel - Venous blood

770

1.31

1.77

8.9

8.7

—

(3025941) Bacteria identified in Stool by Culture

508

1.38

1.76

1.6

1.3

—

(3043924) Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection

136

1103

1.26

1.76

1.7

1.8

—

(3033386) Bacteria [Presence] in Cerebral spinal fluid by Light microscopy

2.45

1.75

1.1

2.3

—

(3009035) Cobalamin (Vitamin B12) [Moles/volume] in Serum or Plasma

238

2051

1.20

1.74

1.7

50000431.16

24926593.89

pmol/l

0.21

202

1693

(3003396) Base excess in Arterial blood by calculation

135

1097

1.26

1.72

7.1

8.1

0.70

1.28

mmol/l

1.05

109

864

(3027946) Carbon dioxide [Partial pressure] in Arterial blood

135

1099

1.26

1.70

7.0

8.1

5.12

kpa

0.01

127

1055

(3007847) Interleukin 2 Receptor Soluble [Units/volume] in Serum or Plasma

2.39

1.68

1.6

3.1

338.60

1427.05

u/ml

—

(3025271) CD3-CD16+CD56+ (Natural killer) cells [#/volume] in Blood

2.19

1.67

3.7

2.1

0.37

0.21

e9/l

1.20

(3017918) Cytomegalovirus IgG Ab [Titer] in Serum or Plasma

188

1.61

1.67

1.4

1.5

—

(3038769) Chlamydophila pneumoniae IgG Ab [Units/volume] in Serum by Immunoassay

3.17

1.66

1.2

1.0

51.88

23.99

u/ml

—

(3026008) Bacteria identified in Urine by Culture

334

2976

1.17

1.65

3.8

3.1

—

(3027801) Oxygen [Partial pressure] in Arterial blood

134

1099

1.25

1.59

7.0

8.1

12.43

12.17

kpa

0.25

127

1056

(40762366) Oxygen capacity [Volume Fraction] in Arterial blood

518

1.35

1.58

9.5

11.2

—

(3020565) Legionella pneumophila DNA [Presence] in Specimen by NAA with probe detection

129

1.72

1.57

1.3

1.5

—

(3048929) Epstein Barr virus Ab [Presence] in Serum

306

1.46

1.56

1.2

—

(3001405) CD3+CD8+ (T8 suppressor) cells [#/volume] in Blood

2.12

1.55

3.9

2.1

442.33

535.45

e6/l

0.40

(3022217) INR in Platelet poor plasma by Coagulation assay

147

1223

1.23

1.54

30.5

25.5

1.64

1.33

inr

0.97

159

(3036489) Thrombin time

349

1.42

1.54

1.9

2.1

23.33

21.45

0.42

310

(3045414) Leukocytes [Presence] in Urine

400

1.39

1.54

2.1

1.8

—

(3028369) Herpes simplex virus 1+2 DNA [Presence] in Specimen by NAA with probe detection

100

1.81

1.53

1.2

—

(43054914) Glucose tolerance 2 hours panel - Serum or Plasma

130

1068

1.24

1.53

1.8

1.7

—

(46235355) HIV 1 and 2 tests - Meaningful Use set

194

1662

1.20

1.51

2.1

1.8

—

(3029023) Hepatitis E virus IgG Ab [Presence] in Serum by Immunoassay

2.17

1.51

1.1

1.0

—

(3002222) Hepatitis E virus IgM Ab [Presence] in Serum

2.17

1.51

1.1

1.0

—

(3002619) Bacteria identified in Specimen by Culture

2.87

1.50

1.0

1.1

—

(43055554) Base excess.100% oxygenated [Moles/volume] standard in Capillary blood by calculation

602

1.32

1.50

2.8

3.7

1.63

1.98

mmol/l

0.24

460

(40760848) Basement membrane zone BP180 Ab [Units/volume] in Serum by Immunoassay

1.96

1.49

1.0

1.4

—

17.36

—

(3011363) Streptococcus pneumoniae Ag [Presence] in Urine

1.96

1.49

1.1

—

(3003327) Ova and parasites identified in Stool by Light microscopy

301

1.44

1.48

1.7

—

(3011960) Natriuretic peptide B [Mass/volume] in Serum or Plasma

783

1.27

1.46

2.7

3.0

204.31

210.54

ng/l

0.04

715

(3014162) Mycobacterium tuberculosis DNA [Presence] in Specimen by NAA with probe detection

319

1.43

1.46

2.2

2.8

—

(3001964) Herpes simplex virus Ag [Presence] in Specimen

2.51

1.45

1.1

1.6

—

(3019284) Hepatitis B virus surface Ag [Presence] in Serum

164

1389

1.21

1.45

1.8

1.6

—

(3012516) Albumin [Mass/volume] in Urine

313

2803

1.16

1.44

3.5

3.3

232.03

330.46

mg/l

0.21

202

1790

(21494815) CD4 cells/100 lymphocytes in Specimen

1.98

1.43

1.3

1.9

—

44.22

—

(3018921) Toxoplasma gondii IgA Ab [Units/volume] in Serum

2.74

1.43

1.2

1.0

—

(40768795) Lymph node Pathology biopsy report

1.83

1.42

1.4

1.1

—

(3009508) Creatinine [Moles/volume] in Urine

334

3009

1.15

1.41

3.5

3.1

7.14

7.56

mmol/l

0.96

278

2523

(3002482) Mycoplasma pneumoniae DNA [Presence] in Specimen by NAA with probe detection

165

1.59

1.41

1.4

1.6

—

(3016502) Oxygen saturation in Arterial blood

120

987

1.24

1.41

7.6

8.5

95.76

95.60

0.08

115

953

(3011951) Aspergillus fumigatus IgE Ab [Units/volume] in Serum

1.86

1.40

1.4

1.2

2.52

0.92

u/ml

—

(3041145) Herpes simplex virus IgM Ab [Presence] in Serum by Immunoassay

2.01

1.38

1.1

1.2

—

(1616796) Gas panel - Central venous blood

207

1.51

1.36

2.6

3.9

—

(42868417) European tick borne encephalitis virus IgG Ab [Presence] in Serum by Immunoassay

2.95

1.36

1.2

—

(4094501)

240

1.47

1.36

1.1

—

(3016650) Hepatitis A virus Ab [Presence] in Serum

151

1.60

1.35

1.0

1.1

—

(3052851) Hemolysis interference index of Serum or Plasma

283

1.43

1.33

4.2

3.1

—

(3002670) Multiple inhalant allergen IgE Ab [Units/volume] in Serum

0.00

1.32

0.0

1.5

—

(46236952) Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD)

750

1.26

1.31

2.0

2.7

69.21

66.14

ml/min/173m2

0.28

316

(3005719) IgG [Mass/volume] in Serum or Plasma

750

1.26

1.31

3.1

2.8

9.94

10.67

g/l

1.19

685

(3032035) Polymorphonuclear cells/100 leukocytes in Blood

201

1.51

1.30

5.0

3.6

56.03

57.97

0.42

201

(3020073) CD3+CD4+ (T4 helper) cells/CD3+CD8+ (T8 suppressor cells) cells [# Ratio] in Specimen

2.51

1.30

1.7

2.2

—

(4133840)

2.51

1.30

1.3

1.1

—

(3027529) Toxoplasma gondii IgM Ab [Units/volume] in Serum

1.77

1.29

1.1

1.2

—

(3021901) Oxygen saturation in Capillary blood

186

1.52

1.27

3.0

2.7

—

(3016616) Dehydroepiandrosterone sulfate (DHEA-S) [Moles/volume] in Serum or Plasma

2.29

1.27

2.4

1.5

4.77

5.20

umol/l

—

(3003031) Transferrin.carbohydrate deficient.disialo/Transferrin.total in Serum or Plasma

133

1121

1.21

1.25

1.7

1.8

1.55

1.46

0.43

117

984

(3011391) Calcitriol [Moles/volume] in Serum or Plasma

1.83

1.25

1.2

1.1

—

(3030905) Polymorphonuclear cells [#/volume] in Blood

195

1.50

1.25

4.7

3.3

4.30

4.35

e9/l

0.04

195

(4015189)

2.41

1.24

1.3

2.5

—

(40760109) Toxoplasma gondii IgG Ab avidity [Ratio] in Serum by Immunoassay

2.41

1.24

1.2

1.0

—

(3009343) pH of Capillary blood

629

1.27

1.24

2.9

3.8

7.42

7.40

0.43

(3023410) Appearance of Cerebral spinal fluid

100

1.71

1.24

1.1

1.6

—

(3012447) Hantavirus puumala IgG Ab [Titer] in Serum

100

1.71

1.24

1.1

—

(3020630) Protein [Mass/volume] in Serum or Plasma

765

1.25

1.23

1.9

3.2

65.28

66.82

g/l

1.62

701

(3013742) Prealbumin [Mass/volume] in Serum or Plasma

110

911

1.23

2.5

2.3

0.22

0.21

g/l

0.67

105

856

(3012477) Bordetella pertussis DNA [Presence] in Specimen by NAA with probe detection

147

1.58

1.23

1.3

1.5

—

(3000570) Elastase.pancreatic [Mass/mass] in Stool

288

1.40

1.22

1.5

299.11

281.63

ug/g

0.23

166

(3010156) C reactive protein [Mass/volume] in Serum or Plasma by High sensitivity method

357

1.36

1.22

1.7

7.60

4.61

mg/l

0.27

268

(3041942) Cyclic citrullinated peptide Ab [Units/volume] in Serum

181

1574

1.18

1.21

1.4

1.3

15.39

13.32

u/ml

0.13

610

(3009041) Cardiolipin IgG Ab [Units/volume] in Serum by Immunoassay

140

1.58

1.20

1.1

1.2

4.13

5.90

u/ml

—

(3003785) Carcinoembryonic Ag [Mass/volume] in Serum or Plasma

119

997

1.22

1.20

4.3

3.52

22.94

ug/l

1.61

822

(3045142) Bone marrow Pathology biopsy report

101

1.69

1.20

1.4

1.3

—

(3021788) Differential panel - Synovial fluid

173

1.51

1.18

1.2

1.6

—

(3013327) Hepatitis A virus IgM Ab [Presence] in Serum

149

1.55

1.17

1.0

1.1

—

(3023520) Reticulocytes [#/volume] in Blood

770

1.24

1.17

2.0

2.6

70.47

71.40

e9/l

0.10

594

(3028679) Herpes simplex virus Ab [Presence] in Serum

2.01

1.16

1.1

1.2

—

(3000494) Fungus identified in Specimen by Culture

135

1149

1.20

1.16

1.5

1.4

—

(3010726) Horse dander IgE Ab [Units/volume] in Serum

134

1.58

1.15

1.0

1.1

0.52

3.33

u/ml

—

(40768443) Skin Pathology biopsy report

423

1.32

1.13

1.2

—

(3014791) Apolipoprotein B [Mass/volume] in Serum or Plasma

1.79

1.11

1.8

1.3

0.87

1.00

g/l

1.33

(3008401) Mugwort IgE Ab [Units/volume] in Serum

136

1.55

1.09

1.0

1.1

0.69

1.92

u/ml

—

(3036432) Mycobacterium tuberculosis genotype [Identifier] in Isolate

1.96

1.09

3.0

4.1

—

(3031478) Chlamydophila pneumoniae DNA [Presence] in Specimen by NAA with probe detection

128

1.57

1.09

1.5

1.6

—

(3007080) Epstein Barr virus nuclear IgG Ab [Units/volume] in Serum

177

1.48

1.08

1.1

1.2

279.65

269.76

u/ml

0.07

106

(3013512) EKG study

305

2786

1.13

1.04

3.8

3.9

—

(3015183) Erythrocyte sedimentation rate

1.96

1.03

1.1

1.2

—

(3000067) Parathyrin.intact [Mass/volume] in Serum or Plasma

755

1.22

1.03

4.0

3.8

84.44

83.49

ng/l

0.04

665

(3023323) Follitropin [Units/volume] in Serum or Plasma

377

1.31

1.03

1.4

28.73

29.56

iu/l

0.06

326

(3007844) Epstein Barr virus capsid IgM Ab [Units/volume] in Serum by Immunoassay

188

1.45

1.02

1.1

1.2

—

(3008909) Norovirus RNA [Presence] in Stool by NAA with probe detection

273

1.37

1.02

1.1

1.2

—

(3045424) Erythrocytes [Presence] in Urine

155

1.49

1.01

1.3

1.4

—

(3014959) Toxoplasma gondii IgG Ab [Units/volume] in Serum

1.62

1.00

2.1

2.4

—

(21493195) Respiratory pathogens DNA and RNA tested for in Respiratory system specimen by NAA with probe detection

2.01

1.00

1.1

1.7

—

(40769539) Bacteria identified based on 16S rRNA gene [Identifier] in Specimen by Sequencing

181

1.45

0.99

1.4

1.6

—

(3005785) Creatine kinase.MB [Mass/volume] in Serum or Plasma

824

1.21

0.98

2.3

2.4

6.05

7.20

ug/l

0.42

724

(3027923) C peptide [Moles/volume] in Serum or Plasma

1.84

0.98

2.3

1.6

1.26

1.31

nmol/l

—

(42868415) European tick borne encephalitis virus IgM Ab [Presence] in Cerebral spinal fluid by Immunoassay

2.18

0.98

1.0

1.3

—

(3006441) Cardiolipin IgM Ab [Presence] in Serum by Immunoassay

2.18

0.98

1.0

—

(40764127) Haemophilus influenzae DNA [Presence] in Specimen by NAA with probe detection

1.86

0.96

1.3

1.6

—

(3006922) Hepatitis E virus Ab [Presence] in Serum

1.86

0.96

1.3

1.0

—

(3037875) Bordetella parapertussis DNA [Presence] in Specimen by NAA with probe detection

1.86

0.96

1.3

1.6

—

(3049717) Cytology report of Urine Cyto stain

373

1.30

0.95

2.4

2.7

—

(3003888) Timothy IgE Ab [Units/volume] in Serum

141

1.50

0.95

1.0

1.1

0.88

6.03

u/ml

2.45

(3040853) Adenovirus DNA [Identifier] in Specimen by NAA with probe detection

225

1.39

0.95

1.4

1.7

—

(21492888) Glucose tolerance 2 hours gestational panel - Serum or Plasma

185

0.59

0.94

1.7

1.6

—

(40768446) Kidney Pathology biopsy report

1.90

0.94

1.7

1.5

—

(3009214) Lutropin [Units/volume] in Serum or Plasma

243

1.37

0.93

1.3

1.4

10.34

10.46

u/l

0.02

198

(21494814) CD8 cells/100 lymphocytes in Specimen

2.23

0.93

1.7

2.1

—

(3023511) Choriogonadotropin [Units/volume] in Urine

167

1.45

0.92

1.5

1.2

—

(3024932) HLA-DR beta [Type]

2.15

0.91

1.0

1.1

—

(3015322) Alpha 1 globulin [Mass/volume] in Serum or Plasma by Electrophoresis

341

1.30

0.90

1.3

2.9

3.05

3.16

g/l

0.29

276

(3001079) Blood group antibody screen [Presence] in Serum or Plasma

488

4607

1.10

0.90

4.4

4.0

—

(3026725) Estradiol (E2) [Moles/volume] in Serum or Plasma

135

1.49

0.89

1.7

1.5

0.92

0.33

nmol/l

0.68

103

(3024471) HLA-A [Type]

2.07

0.89

1.0

—

(3023351) European house dust mite IgE Ab [Units/volume] in Serum

160

1.45

0.89

1.1

2.38

0.87

u/ml

—

(3036481) Cortisol [Moles/volume] in Serum or Plasma

105

899

1.18

0.88

2.5

2.1

359.00

373.63

nmol/l

0.30

830

(3003458) Phosphate [Moles/volume] in Serum or Plasma

142

1247

1.16

0.88

6.5

5.6

1.06

1.04

mmol/l

0.35

135

1150

(3004451) EKG impression Narrative

1.79

0.88

1.1

1.2

—

(3023421) Hepatitis B virus surface Ab [Units/volume] in Serum

281

1.33

0.87

1.3

251.64

254.69

miu/ml

0.01

135

(40766189) Gliadin peptide IgG Ab [Units/volume] in Serum by Immunoassay

264

1.34

0.87

1.1

0.64

7.82

u/ml

—

(40765161) Human bocavirus DNA [Presence] in Specimen by NAA with probe detection

170

1.42

0.85

1.3

1.7

—

(3042194) Human metapneumovirus RNA [Presence] in Specimen by NAA with probe detection

230

1.36

0.85

1.4

1.6

—

(3000855) Microscopic observation [Identifier] in Vaginal fluid by Gram stain

112

1.53

0.85

1.3

1.5

—

(3027545) Mycoplasma pneumoniae Ab [Presence] in Serum by Immunoassay

239

1.35

0.85

1.4

1.3

—

(3011648) Oxygen content in Venous blood

1.63

0.84

2.5

1.7

8.68

11.14

1.47

(3012202) Varicella zoster virus DNA [Presence] in Specimen by NAA with probe detection

1.74

0.82

1.3

1.2

—

(3008733) Herpes simplex virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection

1.74

0.82

1.0

1.2

—

(3029075) Extractable nuclear Ab panel - Serum

1.88

0.82

1.2

1.0

—

(3045783) Sodium and Potassium panel [Moles/volume] - Serum or Plasma

134

1181

1.15

0.80

7.1

6.9

—

(3023465) Gamma globulin [Mass/volume] in Serum or Plasma by Electrophoresis

339

1.28

0.80

1.3

2.8

10.03

10.36

g/l

0.23

294

(3020013) Alkaline phosphatase.intestinal [Enzymatic activity/volume] in Serum or Plasma

1.73

0.79

1.6

1.5

12.40

9.00

u/l

—

(3020682) Albumin/Creatinine [Ratio] in Urine

318

2956

1.10

0.79

4.5

4.0

7.70

9.08

mg/mmol

0.31

207

1867

(3037556) Urate [Mass/volume] in Serum or Plasma

1.82

0.79

1.8

1.2

—

(43055089) Myosin Ab [Presence] in Serum or Plasma by Immunoblot

1.67

0.79

1.0

1.1

—

(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip

390

3663

1.10

0.78

5.0

3.9

—

(3044927) Protein electrophoresis panel - Urine

100

0.50

0.77

1.0

1.1

—

(3011985) Renin [Units/volume] in Plasma

115

1.49

0.77

1.9

1.4

57.90

43.28

mu/l

0.18

106

(3021440) Promyelocytes/100 leukocytes in Blood

772

1.18

0.76

4.7

4.1

0.05

0.13

0.84

211

(3005156) Respiratory syncytial virus A RNA [Presence] in Specimen by NAA with probe detection

1.77

0.76

1.0

1.7

—

(3037692) Legionella sp identified in Specimen by Organism specific culture

1.77

0.76

1.3

1.6

—

(3000108) Respiratory syncytial virus B RNA [Presence] in Specimen by NAA with probe detection

1.77

0.76

1.0

1.7

—

(44806420)

0.00

0.76

0.0

2.3

—

(3042936) Bacteria identified in Isolate by Culture

158

1415

1.13

0.76

2.0

—

(40767503) Oxygen content in Capillary blood by calculation

201

1.35

0.75

2.8

2.5

16.35

16.05

0.14

106

(3006093) Chlamydia trachomatis DNA [Presence] in Specimen by NAA with probe detection

561

1.21

0.74

2.5

1.9

—

(40761539) Cells [Type] in Urine sediment by Light microscopy

2.09

0.74

1.2

1.0

—

(3008037) Lactate [Moles/volume] in Venous blood

219

0.68

0.73

4.3

3.3

1.42

1.56

mmol/l

0.35

214

(3028626) Oxygen [Partial pressure] in Capillary blood

237

1.32

0.73

3.1

2.9

7.93

8.09

kpa

0.26

217

(3004588) Protein electrophoresis panel - Serum or Plasma

646

1.19

0.72

1.9

2.8

—

(3034603) RHD gene allele [Genotype] in Blood or Tissue by Molecular genetics method Nominal

1.80

0.72

1.7

1.4

—

(37020957) Sapovirus genogroups I+II+IV+V RNA [Presence] in Stool by NAA with probe detection

1.61

0.72

1.1

1.2

—

(3045684) Alkaline phosphatase.other fractions [Enzymatic activity/volume] in Serum or Plasma

1.61

0.72

1.2

27.89

15.37

u/l

—

(42869457) Rotavirus RNA [Identifier] in Stool by NAA with probe detection

1.61

0.72

1.1

1.3

—

(3002179) Metamyelocytes/100 leukocytes in Blood

749

1.17

0.72

4.6

3.9

0.22

0.62

2.17

173

(3014133) Dog dander IgE Ab [Units/volume] in Serum

117

1.46

0.72

1.0

2.15

3.49

u/ml

—

(3023430) Cat dander IgE Ab [Units/volume] in Serum

109

1.47

0.71

1.0

2.64

5.13

u/ml

—

(3009871) Measles virus Ab [Titer] in Serum

1.93

0.70

2.0

1.7

—

(42529406) Shigella sp [Presence] in Stool by Culture

283

1.28

0.70

1.4

1.2

—

(3022575) Varicella zoster virus IgG Ab [Units/volume] in Serum

1.71

0.70

1.0

1.1

1036.00

1862.05

miu/ml

—

(3035400) Alkaline phosphatase.liver [Enzymatic activity/volume] in Serum or Plasma

1.56

0.70

1.2

77.67

79.47

u/l

—

(3016018) Differential panel - Cerebral spinal fluid

1.51

0.69

1.1

1.5

—

(3018006) Microscopic observation [Identifier] in Cervix by Cyto stain.thin prep

167

1511

1.12

0.69

1.5

1.4

—

(3019150) Specific gravity of Urine by Refractometry

227

2090

1.11

0.69

5.0

4.1

1.02

kg/l

0.38

306

(3050238) Crystals [Presence] in Synovial fluid by Light microscopy

266

1.29

0.69

1.4

1.3

—

(3042596) Human coronavirus RNA [Presence] in Specimen by NAA with probe detection

110

1.46

0.68

1.4

1.7

—

(42868421) Varicella zoster virus IgM Ab [Presence] in Cerebral spinal fluid by Immunoassay

1.86

0.68

1.0

1.3

—

(3042733) HLA Ab [Presence] in Serum

1.86

0.68

7.8

4.8

—

(40761849) Varicella zoster virus IgG Ab [Units/volume] in Cerebral spinal fluid by Immunoassay

1.86

0.68

1.0

1.2

—

(3005791) Eosinophil cationic protein (ECP) [Mass/volume] in Serum

1.67

0.68

2.0

9.83

220.04

ug/l

—

(42868674) Cholesterol in HDL/Cholesterol.total [Molar ratio] in Serum or Plasma

133

1189

1.13

0.67

4.4

31.66

32.32

0.23

799

(3029536) Hepatitis C virus RNA [Units/volume] (viral load) in Specimen by NAA with probe detection

1.63

0.67

1.1

1.5

—

1224630.00

—

(3046524) Influenza virus A Ag [Presence] in Nasopharynx by Immunoassay

197

1.33

0.66

1.0

1.4

—

(3043362) Influenza virus B Ag [Presence] in Nasopharynx by Immunoassay

197

1.33

0.66

1.0

1.4

—

(3008714) Choriogonadotropin [Multiple of the median] adjusted in Serum or Plasma

206

1.32

0.66

1.5

1.4

—

(46235831) Pregnancy associated plasma protein A [Multiple of the median] adjusted in Serum or Plasma

206

1.32

0.66

1.5

1.4

—

(40763531) Fetal Nuchal fold [Multiple of the median] Thickness adjusted for maternal weight

206

1.32

0.66

1.5

1.4

—

(3049207) Fetal Trisomy 21 risk [Likelihood] Based on maternal age

206

1.32

0.66

1.5

1.4

—

(37021247) Adenovirus 40+41 DNA [Presence] in Stool by NAA with probe detection

1.59

0.65

1.1

1.2

—

(37020445) Astrovirus RNA [Presence] in Stool by NAA with probe detection

1.59

0.65

1.1

1.2

—

(3032699) Streptococcus pneumoniae DNA [Presence] in Specimen by NAA with probe detection

1.62

0.65

1.3

1.5

—

(1001509) Gas and Carbon monoxide and Electrolytes panel - Arterial blood

1.62

0.65

1.6

2.3

—

(46235759) Influenza virus B RNA [Presence] in Nasopharynx by NAA with probe detection

386

1.23

0.65

1.6

1.9

—

(3025159) Blasts/100 leukocytes in Blood

738

1.16

0.65

5.0

4.2

0.30

0.57

0.20

182

(3005033) Fetal Nuchal fold Thickness US

163

1.36

0.64

1.5

1.4

—

(3047352) Trisomy 18 risk [Likelihood] in Fetus

163

1.36

0.64

1.6

1.4

—

(3002434) Lupus erythematosus deoxynucleoproteins IgG Ab [Units/volume] in Serum by Immunoassay

314

1.25

0.64

1.8

—

(4062490)

1.50

0.63

3.3

1.3

—

(3020779) Urea [Moles/volume] in Serum or Plasma

834

1.15

0.63

6.5

7.2

8.71

9.78

mmol/l

1.02

791

(3000924) Streptococcus pyogenes [Presence] in Throat by Organism specific culture

103

0.58

0.62

1.5

1.2

—

(3043747) Beta 2 globulin [Mass/volume] in Serum or Plasma by Electrophoresis

361

1.23

0.62

1.3

2.8

3.93

3.76

g/l

0.49

271

(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection

1.64

0.62

1.0

1.3

—

(3004915) Chlamydophila pneumoniae IgA Ab [Units/volume] in Serum

1.59

0.62

1.1

1.0

—

(3005570) Glucose [Moles/volume] in Urine

105

0.57

0.62

2.2

2.3

—

(40771527) Human papilloma virus E6+E7 mRNA [Presence] in Cervix by NAA with probe detection

1.67

0.61

1.4

1.6

—

(3016879) Cocaine [Presence] in Urine

323

0.77

0.61

2.4

1.7

—

(3005229) Alpha 2 globulin [Mass/volume] in Serum or Plasma by Electrophoresis

362

1.22

0.61

1.3

2.8

7.43

7.41

g/l

0.02

278

(3043723) Beta 1 globulin [Mass/volume] in Serum or Plasma by Electrophoresis

362

1.22

0.61

1.3

2.8

—

(3017895) Helicobacter pylori Ab [Units/volume] in Serum

335

1.23

0.60

1.8

1.6

—

(3016251) Hemoglobin.gastrointestinal [Presence] in Stool

482

1.19

0.60

2.2

2.4

—

(40766183) Gliadin peptide IgA Ab [Units/volume] in Serum by Immunoassay

131

1.38

0.59

1.1

1.0

1.54

2.12

u/ml

—

(3041096) Erythrocytes [Presence] in Urine by Automated

280

2625

1.09

0.59

4.2

3.4

—

(3012501) Base excess in Blood by calculation

210

1.29

0.59

2.4

4.5

2.48

2.79

mmol/l

0.23

143

(3008295) Osmolality of Serum or Plasma

114

1.41

0.59

2.0

1.4

289.90

280.05

mosm/kgh2o

—

(3049539) Genetic diseases [Identifier] in Blood or Tissue by FISH Nominal

1.57

0.58

1.7

1.2

—

(1761482) Bacteria [#/volume] in Urine by Culture

253

0.75

0.58

3.7

4.7

—

(3035637) Corticotropin [Mass/volume] in Plasma

106

1.42

0.57

1.1

1.6

—

(3028300) Cannabinoids [Presence] in Urine

353

0.79

0.57

2.3

1.7

—

(3000012) Reticulocyte production index

1.48

0.57

1.3

1.8

—

(3021337) Troponin I.cardiac [Mass/volume] in Serum or Plasma

197

1822

1.10

0.56

3.5

3.8

751.36

350.48

ng/l

0.45

150

1406

(3027008) Opiates [Presence] in Urine

351

0.79

0.55

2.3

1.7

—

(3011371) Neisseria gonorrhoeae DNA [Presence] in Specimen by NAA with probe detection

450

1.19

0.55

2.2

1.7

—

(3022313) Gas panel - Capillary blood

469

1.18

0.54

3.0

3.9

—

(3000764) Benzodiazepines [Presence] in Urine

350

0.80

0.54

2.3

1.7

—

(3013566) Clostridioides difficile [Presence] in Stool by Organism specific culture

1.58

0.54

1.0

1.3

—

(3021952) Alkaline phosphatase isoenzymes [Enzymatic activity/volume] in Serum or Plasma by Heat stability

151

1.33

0.54

1.2

—

(3027238) Thyroperoxidase Ab [Units/volume] in Serum or Plasma

666

1.15

0.54

1.3

1.2

221.87

138.73

iu/ml

0.64

261

(3030408) 3-Methoxytyramine [Moles/volume] in Serum or Plasma

125

1.37

0.53

1.0

1.3

—

0.63

nmol/l

—

(3012220) Varicella zoster virus IgM Ab [Presence] in Serum by Immunoassay

125

1.37

0.53

1.1

—

(3046279) Procalcitonin [Mass/volume] in Serum or Plasma

382

0.81

0.53

1.7

1.9

2.07

2.25

ug/l

0.04

336

(3027944) Amphetamines [Presence] in Urine

349

0.80

0.53

2.0

1.6

—

(586526) SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with probe detection

564

1.16

0.53

1.4

1.5

—

(3053028) Streptococcus sp identified in Specimen by Organism specific culture

1.43

0.52

1.4

—

(3014765) Yersinia sp identified in Stool by Organism specific culture

278

1.23

0.51

1.4

1.2

—

(3043238) Trisomy 21 risk [Likelihood] in Fetus

170

1.30

0.51

1.7

1.5

—

(3035320) C reactive protein [Mass/volume] in Body fluid

1.39

0.50

3.9

2.1

—

(3025023) Rhinovirus RNA [Presence] in Specimen by NAA with probe detection

1.42

0.50

1.2

1.7

—

(3000475) Leukocytes [#/volume] in Synovial fluid

234

1.25

0.50

1.8

1.7

7280.08

14073.28

e6/l

1.17

178

(36304997) Mycobacterium tuberculosis stimulated gamma interferon release by CD4+ and CD8+ T-cells [Units/volume] in Blood

307

1.21

0.49

1.6

0.01

20.76

iu/ml

—

(3010380) Borrelia burgdorferi IgG Ab [Units/volume] in Cerebral spinal fluid

101

1.39

0.49

1.1

—

(4010399)

681

1.14

0.49

1.7

1.4

—

(3003265) Liver kidney microsomal Ab [Titer] in Serum by Immunofluorescence

1.43

0.49

1.3

1.2

—

(3026389) Candida sp identified in Specimen by Organism specific culture

119

1.35

0.48

1.6

1.4

—

(3022756) Ceruloplasmin [Mass/volume] in Serum or Plasma

1.45

0.48

1.0

327.64

280.21

mg/l

0.89

(3037121) Protein [Mass/volume] in Urine

336

1.20

0.48

3.4

3.5

0.82

0.31

g/l

0.80

145

(3048816) Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Blood

797

1.13

0.47

4.6

3.7

1.22

1.23

mmol/l

0.45

693

(3016881) Enterovirus RNA [Presence] in Specimen by NAA with probe detection

102

1.38

0.47

1.1

1.6

—

(1761868) Lipid panel - Serum or Plasma

324

3401

0.93

0.47

2.8

—

(40768800) Prostate Pathology biopsy report

173

1.28

0.46

1.1

1.2

—

(3044254) Respiratory syncytial virus RNA [Presence] in Specimen by NAA with probe detection

356

1.19

0.46

1.5

1.7

—

(3017181) Myelocytes/100 leukocytes in Blood

819

1.12

0.45

4.8

4.0

0.64

0.95

0.77

234

(3044355) Beta 2 glycoprotein 1 IgG Ab [Units/volume] in Serum or Plasma by Immunoassay

138

1.31

0.45

1.2

1.00

3.80

u/ml

—

(3020321) Streptococcus agalactiae [Presence] in Vaginal fluid by Organism specific culture

209

0.76

0.45

1.4

1.6

—

(3009340) Metanephrine [Moles/volume] in Serum or Plasma

112

1.34

0.44

1.1

1.3

—

nmol/l

—

(3006571) Polymorphonuclear cells/100 leukocytes in Synovial fluid

121

1.33

0.44

1.2

1.6

46.45

58.32

0.63

(3002523) Influenza virus A Ag [Presence] in Specimen

152

0.72

0.44

1.5

1.1

—

(3007778) Kappa light chains/Lambda light chains [Mass Ratio] in Serum

284

1.20

0.44

3.0

4.2

2.36

1.77

ratio

—

(3011288) Drugs identified in Urine by Screen method

230

0.78

0.44

3.0

2.5

—

(42868544) Hantavirus puumala IgM Ab [Presence] in Serum or Plasma by Immunofluorescence

148

1.29

0.43

1.2

1.1

—

(3044290) Cell count panel - Cerebral spinal fluid

193

1.25

0.43

1.1

1.4

—

(40764126) Parainfluenza virus RNA [Presence] in Specimen by NAA with probe detection

1.41

0.43

1.4

1.6

—

(3003740) Influenza virus B Ag [Presence] in Specimen

151

0.73

0.43

1.5

1.1

—

(3006418) Campylobacter sp identified in Tissue by Organism specific culture

276

1.20

0.42

1.4

1.2

—

(4268621)

1.38

0.42

2.2

2.3

—

(21494890) Protein electrophoresis panel - 24 hour Urine

1.36

0.41

1.5

2.3

—

(3035457) Cefaclor IgE Ab [Units/volume] in Serum

0.00

0.41

0.0

1.1

—

(21494755) Public health laboratory ask at order entry panel

866

0.89

0.41

1.4

1.3

—

(3020951) Lymphocytes/100 leukocytes in Cerebral spinal fluid

0.00

0.41

0.0

1.2

—

45.60

—

(3015479) Mycobacterium sp identified in Blood by Organism specific culture

0.00

0.41

0.0

1.4

—

(40768441) Liver Pathology biopsy report

1.40

0.40

1.5

1.2

—

(3000213) Normetanephrine [Moles/time] in 24 hour Urine

0.00

0.40

0.0

1.2

—

1.83

—

(3003985) Beta hydroxybutyrate [Moles/volume] in Serum or Plasma

0.00

0.40

0.0

2.1

—

0.87

—

(3045781) Inhibin B [Mass/volume] in Serum or Plasma

0.00

0.40

0.0

2.3

—

55.37

—

(3051611) Lipemic interference index of Serum or Plasma

1.34

0.39

5.5

3.3

—

(3017732) Neutrophils [#/volume] in Blood

646

1.12

0.39

2.3

2.9

5.07

4.06

e9/l

1.43

508

(3019832) Treponema pallidum Ab [Presence] in Serum

867

1.10

0.39

1.8

1.6

—

(3038177) Helicobacter pylori Ab [Presence] in Serum

133

1.28

0.38

1.3

1.2

—

(3019145) Choriogonadotropin.beta subunit free [Mass/volume] in Serum or Plasma

224

1.21

0.38

1.6

1.5

—

(3006257) Acetylcholine receptor Ab [Moles/volume] in Serum

1.38

0.38

1.0

1.1

—

1.47

—

(3024891) Influenza virus A+B Ag [Presence] in Specimen

258

0.81

0.38

1.0

1.1

—

(44813793)

1.37

0.38

1.0

1.1

—

(3016724) Homocysteine [Moles/volume] in Serum or Plasma

1.37

0.38

1.1

1.6

11.89

13.18

umol/l

—

(3051651) Icteric interference index of Serum or Plasma

1.37

0.38

5.4

3.3

—

(42869547) Procollagen type III.N-terminal propeptide [Mass/volume] in Serum

1.39

0.38

2.0

1.3

7.00

8.80

ug/l

—

(3028433) Virus identified in Specimen by Culture

1.39

0.38

1.0

1.1

—

(3023150) Myeloperoxidase Ab [Units/volume] in Serum

161

1.25

0.37

4.0

1.4

—

(3002109) Cholesterol in LDL/Cholesterol in HDL [Mass Ratio] in Serum or Plasma

793

1.10

0.37

1.6

1.7

—

(3037756) Immunofixation for Serum or Plasma

217

1.20

0.35

1.2

1.8

—

(21493466) Plesiomonas shigelloides DNA [Presence] in Stool by NAA with non-probe detection

122

0.74

0.35

1.2

1.4

—

(3025468) Yersinia sp identified in Specimen by Organism specific culture

122

0.74

0.35

1.2

1.4

—

(3015816) F5 gene p.Arg506Gln [Presence] in Blood or Tissue by Molecular genetics method

135

1.26

0.35

1.1

—

(42868716) Shigella species+EIEC invasion plasmid antigen H ipaH gene [Presence] in Stool by NAA with probe detection

123

0.73

0.35

1.2

1.3

—

(3005988) Vibrio sp identified in Specimen by Organism specific culture

123

0.73

0.35

1.2

1.4

—

(3024522) Salmonella sp identified in Specimen by Organism specific culture

125

0.72

0.35

1.2

1.3

—

(3012568) Campylobacter sp identified in Specimen by Organism specific culture

125

0.72

0.35

1.2

1.4

—

(40759812) SCL-70 extractable nuclear Ab [Presence] in Serum by Immunoblot

1.37

0.34

1.4

1.1

—

(40759849) Smith extractable nuclear Ab [Presence] in Serum by Immunoblot

1.37

0.34

1.4

1.1

—

(40759836) Histone Ab [Presence] in Serum by Immunoblot

1.37

0.34

1.4

1.1

—

(3011831) Apolipoprotein B/Apolipoprotein A-I [Percentile]

1.37

0.34

1.0

1.4

—

(3012158) Parainfluenza virus 2 RNA [Presence] in Specimen by NAA with probe detection

1.34

0.33

1.0

1.6

—

(3006262) Parainfluenza virus 3 RNA [Presence] in Specimen by NAA with probe detection

1.34

0.33

1.0

1.6

—

(3038297) Parainfluenza virus 4 RNA [Presence] in Specimen by NAA with probe detection

1.34

0.33

1.0

1.6

—

(3025634) Parainfluenza virus 1 RNA [Presence] in Specimen by NAA with probe detection

1.34

0.33

1.0

1.6

—

(3018171) Choriogonadotropin [Units/volume] in Serum or Plasma

318

0.85

0.33

1.9

2.1

17421.33

3468.16

u/l

—

136

(4306422)

136

1.25

0.33

1.1

1.2

—

(3032155) Metanephrine Free [Moles/volume] in Serum or Plasma

118

1.27

0.33

1.0

1.3

—

(3014148) Varicella zoster virus Ab [Titer] in Serum

118

1.27

0.33

1.1

1.2

—

(3050129) First trimester maternal screen panel - Serum or Plasma

266

1.17

0.32

1.3

1.5

—

(3019225) pH of Specimen

104

964

1.09

0.32

4.0

4.2

—

(40759843) Sjogrens syndrome-A extractable nuclear Ab [Presence] in Serum by Immunoblot

1.35

0.32

1.4

1.1

—

(40759842) Ribonucleoprotein extractable nuclear Ab [Presence] in Serum by Immunoblot

1.35

0.32

1.4

1.1

—

(40759844) Sjogrens syndrome-B extractable nuclear Ab [Presence] in Serum by Immunoblot

1.35

0.32

1.4

1.1

—

(3003694) ABO and Rh group [Type] in Blood

258

2690

0.95

0.31

1.4

—

(3050380) Cytology report of Cervical or vaginal smear or scraping Cyto stain

305

1.15

0.31

1.5

1.4

—

(3027475) Erythrocytes [#/volume] in Cerebral spinal fluid

221

1.18

0.30

1.1

1.5

136.40

664.73

e6/l

0.55

181

(3016543) Leukocytes [#/volume] in Cerebral spinal fluid

221

1.18

0.30

1.1

1.4

1.89

9.23

e6/l

1.48

176

(3010838) Calcium [Moles/time] in 24 hour Urine

1.30

0.30

1.9

1.6

—

10.79

—

(3020287) Protein C actual/normal in Platelet poor plasma by Coagulation assay

129

1.24

0.30

1.1

116.81

115.37

0.07

120

(3020891) Body temperature

377

0.87

0.29

5.8

4.3

—

(3030692) Respiratory virus DNA+RNA [Identifier] in Specimen by NAA with probe detection

139

1.23

0.29

1.5

1.6

—

(3017569) Oxygen content in Arterial blood

1.23

0.29

2.7

3.2

—

(40762485) Glomerular basement membrane Ab [Units/volume] in Serum by Immunoassay

1.30

0.28

2.9

1.1

—

(1001926) Buprenorphine [Presence] in Urine by Screen method

268

0.86

0.27

2.5

1.8

—

(3041354) Potassium [Moles/volume] in Venous blood

128

0.78

0.27

3.4

2.8

3.97

4.05

mmol/l

—

128

(3035285) Chloride [Moles/volume] in Venous blood

128

0.78

0.27

3.4

2.8

106.00

105.39

mmol/l

—

128

(44790047)

113

1.24

0.26

1.5

1.6

—

(44806118)

113

1.24

0.26

1.5

1.6

—

(44790048)

113

1.24

0.26

1.5

1.6

—

(44790049)

113

1.24

0.26

1.5

1.6

—

(3022621) pH of Urine by Test strip

616

1.09

0.26

3.1

2.9

—

(3024928) Oxygen saturation in Venous blood

206

1.17

0.26

3.1

2.7

—

(3006442) Creatine [Moles/volume] in Serum or Plasma

0.70

0.26

1.0

1.5

—

69.29

—

(40759883) Oligoclonal Bands IgG [Presence] in Cerebral spinal fluid by Isoelectric focusing

0.70

0.26

1.0

—

(3024474) Albumin [Mass/volume] in Cerebral spinal fluid

0.69

0.26

1.0

1.1

200.40

237.63

mg/l

—

(37020937) Giardia lamblia DNA [Presence] in Stool by NAA with probe detection

0.69

0.26

1.2

1.3

—

(3043405) Microscopic observation [Identifier] in Specimen by Non-gynecological cytology method

1.27

0.24

1.5

1.4

—

(3004616) Nuclear Ab [Presence] in Serum

115

1.22

0.23

1.6

1.3

—

(3019060) Gas panel - Arterial blood

650

1.08

0.23

4.4

5.4

—

(1175715) Chlamydophila pneumoniae IgM Ab [Presence] in Serum by Immunoassay

136

0.81

0.23

1.2

1.1

—

(37020300) Entamoeba histolytica DNA [Presence] in Stool by NAA with probe detection

1.28

0.23

1.2

1.3

—

(3050449) Albumin [Mass/time] in Urine collected for unspecified duration

247

1.14

0.22

3.1

2.4

147.05

96.56

ug/min

0.23

150

(3042111) Morphology [Interpretation] in Bone marrow Narrative

157

0.83

0.22

2.5

1.6

—

(3000330) Specific gravity of Urine by Test strip

472

0.91

0.22

2.7

3.6

—

(3030429) Borrelia sp DNA [Identifier] in Specimen by NAA with probe detection

1.22

0.22

1.0

—

(3009466) Valproate [Moles/volume] in Serum or Plasma

144

1.18

0.22

3.5

5.3

372.83

366.01

umol/l

0.05

128

(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay

305

1.12

0.22

2.7

2.6

0.29

0.36

u/ml

0.90

165

(3033705) Calcium.ionized [Moles/volume] in Venous blood

124

0.80

0.21

3.4

2.8

—

(3048469) 10-Hydroxycarbazepine [Moles/volume] in Serum or Plasma

1.19

0.21

1.8

2.4

49.40

47.94

umol/l

—

(3014043) Spermatozoa Nonprogressive/100 spermatozoa in Semen

0.00

0.21

0.0

4.4

—

(3036312) Salmon IgE Ab [Units/volume] in Serum

0.00

0.21

0.0

1.0

—

0.36

—

(40761995) Spermatozoa Progressive [#/volume] in Semen

0.00

0.21

0.0

2.2

—

(3011544) Albumin [Mass/volume] in Pleural fluid

0.00

0.21

0.0

1.0

—

17.64

—

(3046299) Protein.monoclonal [Mass/volume] in Serum or Plasma by Electrophoresis

0.00

0.21

0.0

7.1

—

(37021073) Hepatitis C virus genotype in Serum or Plasma by Sequencing

0.00

0.21

0.0

1.1

—

(3010521) Mycoplasma pneumoniae IgM Ab [Presence] in Serum by Immunoassay

239

1.13

0.21

1.3

1.1

—

(3042552) Rheumatoid factor [Units/volume] in Pleural fluid

0.00

0.21

0.0

1.0

—

10.80

—

(3047166) Epithelial cells [#/area] in Urine sediment by Automated count

0.00

0.21

0.0

3.3

—

0.58

—

(40768806) Pleura Pathology biopsy report

103

0.78

0.21

1.1

1.5

—

(3011166) Borrelia burgdorferi Ab [Presence] in Cerebral spinal fluid

1.24

0.21

1.0

1.1

—

(3050794) Legionella sp Ab [Presence] in Serum

0.00

0.21

0.0

1.1

—

(40760007) HIV 1+2 Ab+HIV1 p24 Ag [Presence] in Serum or Plasma by Immunoassay

0.00

0.20

0.0

1.1

—

(3041870) Hepatitis C virus IgG Ab [Presence] in Serum or Plasma by Immunoassay

0.00

0.20

0.0

1.1

—

(3013293) Extractable nuclear Ab [Presence] in Serum

0.00

0.20

0.0

1.9

—

(3006588) Cancer Ag 15-3 [Units/volume] in Serum or Plasma

183

1.15

0.20

4.1

3.6

14.03

32.60

u/ml

2.11

178

(3042975) Streptococcus sp identified in Isolate by Organism specific culture

1.18

0.19

1.2

—

(3010566) Parathyrin.intact [Moles/volume] in Serum or Plasma

165

1.15

0.19

3.4

3.0

—

(3043109) Cytology report of Tissue fine needle aspirate Cyto stain

259

0.89

0.18

1.1

1.2

—

(36032419) SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Immunoassay

332

0.90

0.18

1.5

1.8

—

(3008757) Leukocyte morphology finding [Identifier] in Blood

110

1.18

0.17

3.5

—

(3001019) Free T4 and TSH panel - Serum or Plasma

485

0.92

0.17

1.7

1.6

—

(40761536) Microorganisms panel - Urine sediment

846

1.06

0.17

7.2

3.9

—

(3014051) Protein [Presence] in Urine by Test strip

205

1.12

0.17

2.1

2.0

—

(40768793) Breast Pathology biopsy report

236

0.89

0.17

1.3

—

(40760888) Immunoglobulin light chains.free panel - Serum

225

0.89

0.16

4.0

4.4

—

(3004716) Salmonella sp identified in Stool by Organism specific culture

506

1.07

0.16

1.7

1.3

—

(1617658) Protocol used for examination of sentinel lymph nodes

0.76

0.15

1.0

1.1

—

(3000093) Morphology [Interpretation] in Blood Narrative

0.79

0.14

1.0

1.2

—

(3016914) Bacteria identified in Cerebral spinal fluid by Culture

1.18

0.14

1.0

1.7

—

(3038546) Human coronavirus OC43 RNA [Presence] in Specimen by NAA with probe detection

1.19

0.14

1.1

1.5

—

(3041642) Human coronavirus 229E RNA [Presence] in Specimen by NAA with probe detection

1.19

0.14

1.1

1.5

—

(3040359) Human coronavirus NL63 RNA [Presence] in Specimen by NAA with probe detection

1.19

0.14

1.1

1.5

—

(4281824)

107

0.84

0.13

1.8

1.1

—

(3029511) Human papilloma virus DNA [Presence] in Specimen by NAA with probe detection

306

1.08

0.13

1.4

—

(3042631) Mycobacterium sp identified in Specimen

142

1.13

0.12

2.2

2.7

—

(3017817) Protein [Mass] in Urine collected for unspecified duration

1.18

0.12

2.7

2.3

—

(21494434) Karyotype in Bone marrow

1.18

0.12

1.0

1.2

—

(3020876) Protein [Mass/time] in 24 hour Urine

1.18

0.12

1.2

2.0

—

1.42

—

(36305247) Microscopic observation [Identifier] in Isolate by Gram stain

279

1.08

0.11

1.9

1.6

—

(1002102) Choriogonadotropin.intact+Beta subunit [Mass/volume] in Serum or Plasma

157

0.89

0.11

1.2

1.5

—

(3042206) Streptococcus agalactiae Ag [Presence] in Vaginal fluid

1.16

0.11

1.3

1.1

—

(3024263) Appearance of Synovial fluid

1.11

0.10

2.8

1.5

—

(4211845)

1.06

0.09

1.4

3.3

—

(3002148) Methylenedioxymethamphetamine [Presence] in Urine by Screen method

1.06

0.09

1.0

1.6

—

(3017315) Amylase [Enzymatic activity/volume] in Urine

1.06

0.09

1.0

1.2

176.60

519.80

u/l

—

(40761535) Cells panel - Urine sediment

774

1.04

0.09

4.6

3.5

—

(40757494) Bilirubin.total [Moles/volume] in Blood

1.11

0.09

3.5

1.7

—

51.34

—

(3018559) Microscopic observation [Identifier] in Buccal smear by Cyto stain

134

0.89

0.08

1.3

1.1

—

(3048402) Erythrocytes [#/area] in Urine sediment by Automated count

1.03

0.08

1.3

1.7

2.00

5.98

u/field

—

(4027681)

0.82

0.08

1.2

1.1

—

(3044491) Cholesterol non HDL [Mass/volume] in Serum or Plasma

539

1.04

0.08

1.4

—

(3044941) Cell count panel - Synovial fluid

156

1.09

0.08

1.9

1.5

—

(3039443) Prostate specific Ag panel - Serum or Plasma

164

0.91

0.08

1.6

1.7

—

(36305771) Cryptosporidium sp DNA [Presence] in Stool by NAA with probe detection

0.82

0.07

1.2

1.3

—

(3040363) Hepatitis A virus IgG Ab [Presence] in Serum by Immunoassay

1.05

0.07

1.0

—

(3012441) Differential panel - Pleural fluid

0.87

0.06

1.3

1.4

—

(3023601) Vancomycin resistant enterococcus [Presence] in Specimen by Organism specific culture

0.86

0.06

2.0

2.5

—

(44816844) Macroprolactin [Units/volume] in Serum or Plasma

1.11

0.06

2.3

1.5

—

(3019902) Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture

104

1019

1.02

0.06

3.8

3.2

—

(3003510) Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection

930

0.98

0.05

2.3

2.0

—

(3008898) HLA-B27 [Presence]

346

1.04

0.05

1.0

1.1

—

(3028707) Methadone [Presence] in Urine by Screen method

151

0.93

0.05

3.1

2.2

—

(1002224) Polysomnography panel

386

1.04

0.05

1.0

1.1

—

(4146454)

110

1.09

0.05

2.8

2.6

—

(3005702) Mycobacterium sp identified in Specimen by Organism specific culture

221

0.95

0.04

1.5

—

(3051387) C reactive protein [Mass/volume] in Capillary blood

210

0.95

0.03

5.1

3.7

31.53

26.81

mg/l

0.24

131

(21494670) JAK2 gene exon 14 targeted mutation analysis in Blood or Tissue by Molecular genetics method

131

1.07

0.03

1.1

1.0

—

(3024950) Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection

101

1024

0.99

0.03

2.4

2.1

—

(3047826) Mullerian inhibiting substance [Mass/volume] in Serum or Plasma

102

1.08

0.03

1.2

1.3

3.18

3.21

ug/l

0.01

(37019628) Gastrointestinal bacterial pathogens panel - Stool by NAA with probe detection

212

1.04

0.02

1.2

1.3

—

(3002032) Base excess in Venous blood by calculation

877

0.99

0.01

4.4

3.6

1.70

2.03

mmol/l

0.39

700

(4034850)

304

0.99

0.00

14.3

11.0

—

(36033641) SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Rapid immunoassay

168

1.01

0.00

1.3

1.6

—

(44816559) Phosphatidylethanol [Mass/volume] in Blood

189

1.01

0.00

1.7

1.2

—

(3024403) Complement+Immunoglobulin [Units/volume] in Red Blood Cells

221

1.00

0.00

1.2

1.5

—

(3033319) Streptococcus pyogenes Ag [Presence] in Throat

871

1.00

0.00

1.4

—

(3020629) Protein S Free Ag actual/normal in Platelet poor plasma by Immunoassay

1.03

0.00

1.1

96.50

94.56

—

(3047007) Chlamydophila sp Ab [Presence] in Serum

127

1.02

0.00

1.3

1.2

—

(3021584) Pregnancy associated plasma protein A [Units/volume] in Serum or Plasma

413

0.99

0.00

1.5

—

(3038864) risperiDONE [Moles/volume] in Serum or Plasma

0.00

0.0

1.0

—

10.60

—

(40760410) HLA-B [Type] by High resolution

0.00

0.0

1.0

—

(3025886) Oxalate [Mass/time] in 24 hour Urine

0.00

0.0

1.0

—

(3007302) Hemoglobin [Mass/volume] in Mixed venous blood

0.00

0.0

5.0

—

(3013466) aPTT in Blood by Coagulation assay

0.00

0.0

1.0

—

34.26

—

(3001334) Neutrophil cytoplasmic Ab [Units/volume] in Serum

0.00

0.0

1.0

—

(3013862) HLA-DP [Type]

0.00

0.0

1.0

—

(21494567) Legionella sp IgM Ab [Presence] in Serum

0.00

0.0

1.0

—

(3017400) Magnesium [Moles/volume] in Urine

0.00

0.0

1.0

—

2.86

—

(40760409) HLA-A [Type] by High resolution

0.00

0.0

1.0

—

(3009677) Dengue virus Ab [Presence] in Serum

0.00

0.0

1.0

—

(3014114) Aureobasidium pullulans IgG Ab [Mass/volume] in Serum

0.00

0.0

1.0

—

(40763590) HLA-DQ beta [Type]

0.00

0.0

1.0

—

(40758358) Immune stain study

0.00

0.0

1.0

—

(3009876) Amylase isoenzyme 3 panel - Serum or Plasma

0.00

0.0

1.2

—

(3040668) CNBP gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal

0.00

0.0

1.0

—

(3008402) Methanol [Moles/volume] in Serum or Plasma

0.00

0.0

2.0

—

(4212803)

0.00

0.0

1.0

—

(3032743) Legionella sp IgG Ab [Presence] in Serum

0.00

0.0

1.0

—

(46234834) Bacteria identified in Bone by Anaerobe+Aerobe culture

0.00

0.0

1.1

—

(3045788) Cell count panel - Pleural fluid

1.00

0.00

1.3

1.4

—

(40766799) MGMT gene methylation score in Tissue by Molecular genetics method

0.00

0.0

1.0

—

(3018688) Ampicillin IgE Ab [Units/volume] in Serum

0.00

0.0

1.0

—

(3034092) Cytoplasmic Ig cells/100 cells in Blood

0.00

0.0

5.3

—

(3044416) Complement C4 [Mass/volume] in Pleural fluid

0.00

0.0

1.0

—

0.06

—

(3015616) Isopropanol [Moles/volume] in Serum or Plasma

0.00

0.0

2.3

—

(46236302) HLA-C [Type] by High resolution typing

0.00

0.0

1.0

—

(3027544) Mycobacterium sp identified in Sputum by Organism specific culture

100

1.00

0.00

3.0

3.8

—

(3008152) Bicarbonate [Moles/volume] in Arterial blood

620

1.00

0.00

7.5

7.6

25.02

24.60

mmol/l

0.49

579

(3042391) t(9;22)(q34.1;q11)(ABL1,BCR) e1a2 fusion transcript/control transcript [# Ratio] in Blood or Tissue by Molecular genetics method

0.00

0.0

3.7

—

(3014271) Vancomycin [Susceptibility]

1.00

0.00

2.6

2.4

—

(3030313) Adrenal Ab [Titer] in Serum

0.00

0.0

1.0

—

(3044242) Glucose [Moles/volume] in Arterial blood

1.00

0.00

2.3

3.1

—

(3032773) Endomysium IgG Ab [Titer] in Serum

0.95

0.00

1.2

1.1

—

(3020393) Adenovirus Ag [Presence] in Stool

0.00

0.0

1.0

—

(3019601) Blood group antibody investigation [Interpretation] in Plasma or RBC

1.01

0.00

2.1

1.6

—

(3020491) Glucose [Moles/volume] in Blood

0.89

0.00

1.9

1.7

8.77

6.72

mmol/l

—

(3017704) Immunofixation for Urine

0.85

0.00

1.2

1.9

—

(3019420) Tryptase [Mass/volume] in Serum or Plasma

0.88

0.00

1.0

1.4

6.10

6.44

ug/l

—

(3023436) Glucagon [Mass/volume] in Serum or Plasma

0.00

0.0

2.0

—

181.29

—

(3009595) Pneumocystis jiroveci DNA [Presence] in Specimen by NAA with probe detection

0.99

0.00

1.6

1.7

—

(3005812) Immunoglobulin light chains [Presence] in 24 hour Urine

0.00

0.0

2.8

—

(1175310) Leucine-rich glioma-inactivated protein 1 Ab [Presence] in Cerebral spinal fluid by Cell binding immunofluorescent assay

0.00

0.0

1.0

—

(3049506) Microalbumin [Mass/time] in Urine collected for unspecified duration

0.86

0.00

2.0

2.2

—

266.50

—

(3011048) Pyruvate [Moles/volume] in Blood

0.00

0.0

1.1

—

85.50

—

(3019768) Coxiella burnetii Ab [Presence] in Serum

0.00

0.0

1.0

—

(3017509) Phencyclidine [Presence] in Urine

0.00

0.0

1.0

—

(3029790) Creatine kinase.MB [Enzymatic activity/volume] in Serum or Plasma

0.00

0.0

1.6

—

12.71

—

(3047189) Immunofixation for 24 hour Urine

1.02

0.00

1.2

1.7

—

(3006804) Neuronal Ab [Presence] in Cerebral spinal fluid

0.00

0.0

1.0

—

(46235128) Lupus anticoagulant aPTT and dRVVT screening panel W Reflex

0.91

0.00

1.2

1.1

—

(3036535) Thyroglobulin [Mass/volume] in Serum or Plasma

0.93

0.00

4.8

7.6

—

(36659890) Mycobacterial identification panel - Specimen by Molecular genetics method

0.00

0.0

1.6

—

Mortality – FinRegistry

↥

Association

Association between endpoint CD2_BENIGN_CONJUNCTIVA and mortality.

Females

Parameter	HR [95% CI]	p-value
CD2_BENIGN_CONJUNCTIVA	0.859 [0.75, 0.98]	0.028
Birth year	0.999 [0.99, 1.01]	0.882

During the follow-up period (1.1.1998 — 31.12.2019), 382 out of 3763 females with CD2_BENIGN_CONJUNCTIVA died.

Males

Parameter	HR [95% CI]	p-value
CD2_BENIGN_CONJUNCTIVA	0.942 [0.82, 1.08]	0.393
Birth year	0.988 [0.98, 1.0]	0.015

During the follow-up period (1.1.1998 — 31.12.2019), 471 out of 3295 males with CD2_BENIGN_CONJUNCTIVA died.

Mortality risk

Mortality risk for people of age

years, who have CD2_BENIGN_CONJUNCTIVA.

N-year risk	Females	Males
1	0.092%	0.141%
5	0.466%	1.121%
10	1.353%	2.747%
15	2.688%	5.275%
20	5.024%	8.955%

Relationships between endpoints

↥

Index endpoint: CD2_BENIGN_CONJUNCTIVA – Benign neoplasm: Conjunctiva

GWS hits: -

Endpoint

Case Overlap

Survival Analysis

Genetic Correlations

Genetic Signals

N (Jaccard index)

HR [CI]

rg [CI]

Hits

Coloc Hits

FinRegistry

FinnGen

FinRegistry

FinnGen

Toxic effect of soaps and detergents

0 (0.00)

Drug-induced pemphigus

Palatinal maxillary operation

0 (0.00)

Necrobiosis lipoidica, not elsewhere classified

0 (0.00)

0.32 [-0.19, 0.83]

Autoimmune diseases related-to ILD

170 (0.33)

Cytomegaloviral pneumonitis

-0.13 [-0.52, 0.26]

Malignant neoplasm of thymus

0 (0.00)

Other congenital malformations of digestive system

0.03 [-0.44, 0.50]

Sclerosis of liver

0 (0.00)

Carcinoma in situ of middle ear and respiratory system

0 (0.00)

Assault by sharp object

Rapidly progressive nephritic syndrome

0 (0.00)

0.13 [-0.36, 0.62]

Infantile muscular atrophy

Biliary cirrhosis, secondary

0 (0.00)

Abnormal findings on diagnostic imaging of breast

Carcinoma in situ of skin of lip

Other and unspecified erythematous conditions

Traumatic amputation of forearm

0 (0.00)

Any mental disorder, or suicide (or attempt), or psychic disorders complicating pregnancy, partum or puerperum or nerve system disorders, excluding more controls

40 (0.25)

0.09 [-0.18, 0.36]

Hyperimmunoglobulin E [IgE] syndrome

0 (0.00)

ILD medications: prednisolone, methylprednisolone, prednisone

314 (0.34)

Failure of sterile precautions during surgical operation

0 (0.00)

Microcephaly

Carcinoma in situ of penis

0 (0.00)

Right hemicolectomy

Alcohol-induced pseudo-Cushing syndrome

0 (0.00)

Cardiomyopathies, Primary/intrinsic

10 (0.15)

Carcinoma in situ of skin, other sites/unspecified

Abnormality of red blood cells

Traumatic arthropathy

0 (0.00)

Mucopolysaccharidosis, type II

Drug-induced folate deficiency anaemia

0 (0.00)

Hypothermia

0 (0.00)

Use of donepezil

26 (0.29)

Benign neoplasm: Bone and articular cartilage, unspecified

0 (0.00)

-0.24 [-0.87, 0.38]

Other transepidermal elimination disorders

0 (0.00)

Unspecified misadventure during surgical and medical care

Tuberous sclerosis 1

Benzodiazepine use

166 (0.26)

Solar urticaria

0 (0.00)

Mucinous and mucinous cystic tumor

0 (0.00)

Porphyria cutanea tarda

Routine general health check-up of defined subpopulation

Hypertrophy of (infrapatellar) fat pad

0 (0.00)

-0.24 [-1.10, 0.61]

Benign neoplasm: Endocrine gland, other/unspecified

0 (0.00)

Used for control exclusion in common control thyroid runs

417 (0.28)

Beta thalassaemia

0 (0.00)

Pemphigus erythematosus

0 (0.00)

Carcinoma in situ of uteri, other/unspecified

0 (0.00)

Benign neoplasm: Appendix

Other accidental hanging and strangulation

0 (0.00)

Hereditary motor and sensory neuropathy

0 (0.00)

-0.27 [-1.01, 0.47]

Hereditary factor XI deficiency

0 (0.00)

Myelofibrosis

0 (0.00)

Other specified air transport accidents

0 (0.00)

Encephalocele

Hodgkin lymphoma

0.60 [-0.51, 1.71]

Lymphocyte function antigen-1 [LFA-1] defect

0 (0.00)

Abnormal findings in secretions and smears from cervix uteri vagina vulva

62 (0.24)

Calcific aortic valvular stenosis, diagnosis (helper)

36 (0.26)

Subacute thyrotoxicosis, drug-induced

Congenital malformation of biliary tract

-0.32 [-0.89, 0.26]

L02BG Aromatase inhibitors

40 (0.30)

Congenital malformations of pulmonary and tricuspid valves

0 (0.00)

-0.49 [-1.33, 0.36]

Thyrotoxicosis factitia

0 (0.00)

0.04 [-0.38, 0.47]

Nutritional anaemias

64 (0.25)

Listeriosis

0 (0.00)

-0.09 [-0.52, 0.34]

Congenital and developmental myasthenia

0 (0.00)

Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified (FINNGEN)

167 (0.28)

Hereditary angioödema type 1

0 (0.00)

Melanoma in situ of upper limb, including shoulder

0 (0.00)

Asthma (only as main-diagnosis), excluding more controls

152 (0.30)

0.05 [-0.16, 0.26]

Other and specified injuries of hip and thigh

0 (0.00)

Open wounds involving multiple body regions

Lung cancer and mesothelioma

26 (0.23)

Recurrent and persistent haematuria

0.25 [-0.24, 0.74]

Periodontal disease, other/unspecified

0 (0.00)

Testicular dysfunction, other/unspecified

-0.04 [-0.72, 0.63]

Cryoglobulinemia

-0.10 [-0.49, 0.29]

Other and unspecified disorders of adult personality and behaviour

-0.26 [-0.83, 0.30]

Other systemic involvement of connective tissue

51 (0.37)

Malignant neoplasm of respiratory system and intrathoracic organs

28 (0.26)

Lumbar disc prolapse

102 (0.27)

0.18 [-0.10, 0.47]

Phlebitis and thrombophlebitis of lower extremities, unspecified, drug-induced

-0.24 [-1.17, 0.69]

Carcinoma in situ of cervix uteri, exocervix

0 (0.00)

UC patients in KELA-register (code 208), prior to 1994

9 (0.32)

Benign neoplasm: Short bones of upper limb

Idiopathic peripheral autonomic neuropathy

-0.35 [-1.00, 0.30]

Injury, poisoning and certain other consequences of external causes

770 (0.25)

Use of melevodopa decarboxylase inhibitor

Other ill-defined and unspecified causes of mortality

Carcinoma in situ of vulva

Fracture of lower limb, level unspecified

0 (0.00)

Melanoma in situ of other and unspecified parts of face

Toxic effects of substances chiefly nonmedicinal as to source

15 (0.25)

Malignant neoplasm of bronchus and lung, excluding all cancers (controls excluding all cancers)

25 (0.23)

0.09 [-0.28, 0.47]

Bartonellosis

0 (0.00)

Injury of blood vessels at hip and thigh level

0 (0.00)

Ovarian dysfunction: estrogen excess, drug-induced

Iodine-deficiency-related thyroid disorders and allied conditions

0 (0.00)

Disorders of puberty, other/unspecified

0 (0.00)

-0.26 [-0.82, 0.31]

Endometroid carcinoma of ovary

0 (0.00)

Other and unspecified diseases of spleen

0.65 [-0.08, 1.39]

Malignant melanoma, excluding all cancers (controls excluding all cancers)

45 (0.55)

0.19 [-0.22, 0.61]

Explicit viral Sepsis

0 (0.00)

Methotrexate

28 (0.36)

Use of levodopa

Disorder of pancreatic internal secretion, other and/or unspecified

0 (0.00)

-0.07 [-0.60, 0.46]

Malignant neoplasm of head and neck, excluding all cancers (controls excluding all cancers)

12 (0.23)

0.36 [-0.33, 1.04]

Benign neoplasm: Other/unspecified site

Perioral dermatitis, drug-induced

0 (0.00)

Parodontitis, under 40 years and operation codes

5 (0.09)

Benign neoplasm: Epididymis

0 (0.00)

Malignant neoplasm of eye and adnexa, excluding all cancers (controls excluding all cancers)

43 (2.54)

0.46 [-0.18, 1.10]

Labyrinthine fistula

0 (0.00)

-0.27 [-0.71, 0.17]

Dental pulpitis 3, only avohilmo

7 (0.09)

Injury of muscle and tendon at shoulder and upper arm level

54 (0.31)

Benign neoplasm: Aortic body and other paraganglia

0 (0.00)

Problems related to life-management difficulty

16 (0.22)

Use of apomorphine

0 (0.00)

Benign neoplasm: Ribs, sternum and clavicle

Benign neoplasm of bone and articular cartilage

14 (0.31)

Functional disorders of polymorphonuclear neutrophils

0 (0.00)

Benign intracranial hypertension

0.21 [-0.36, 0.79]

Other cestode infections

0.17 [-0.27, 0.62]

Echinococcosis

Carcinoma in situ of rectum

0 (0.00)

Carcinoma in situ of breast, intraductal

11 (0.26)

0.04 [-0.43, 0.51]

Other sex chromosome abnormalities, female phenotype, not elsewhere classified

Adjustment and management of implanted device

31 (0.34)

Adenocarcinoma of pancreas

Other helminthiases

Thromboangiitis obliterans

0 (0.00)

0.30 [-0.24, 0.83]

Malignant neoplasm of other and ill-defined sites, excluding all cancers (controls excluding all cancers)

Malignant neoplasm, without specification of site

6 (0.26)

Benign neoplasm: Mediastinum

0 (0.00)

-0.08 [-0.65, 0.50]

Benign lipomatous neoplasm of intrathoracic organs

0 (0.00)

Benign neoplasm: Extrahepatic bile ducts

0 (0.00)

-0.28 [-0.82, 0.26]

Burns and corrosions of external body surface, specified by site

10 (0.17)

Squamous cell neoplasms and carcinoma of cervix, excluding all cancers (controls excluding all cancers)

0 (0.00)

0.12 [-0.49, 0.74]

Unspecified hairloss

0 (0.00)

Pathological/recurrent dislocation and subluxation of joint, not elsewhere classified

5 (0.10)

Venous complications and haemorrhoids in the puerperium

0.23 [-0.33, 0.78]

Other heart diseases, wide

356 (0.27)

Yellow fever

0 (0.00)

Poisoning by narcotics and psychodysleptics [hallucinogens]

Combinations of oral blood glucose lowering drugs

28 (0.21)

Viral hepatitis, IBD co-morbidity

6 (0.16)

Selective serotonin reuptake inhibitors

260 (0.24)

Calculus of urinary tract in diseases classified elsewhere

0 (0.00)

Streptococcus and staphylococcus as the cause of diseases classified to other chapters

0 (0.00)

0.21 [-0.46, 0.87]

Superficial injuries involving multiple body regions

L01XE Protein kinase inhibitors

7 (0.22)

Kernicterus

0 (0.00)

Malignant neoplasm of liver and intrahepatic bile ducts

TMD related operations

18 (0.21)

Acquired absence of limb

0 (0.00)

Brain astrocytoma

0 (0.00)

Persons encountering health services for specific procedures and health care

252 (0.30)

Other inflammatory disorders of orbit (ICD-8 only)

0 (0.00)

Indeterminate sex and pseudohermaphroditism

0 (0.00)

Other nutritional deficiencies

100 (0.28)

Von Hippel-Lindau syndrome

Disorders of lens

326 (0.35)

Unspecified multiple injuries

Discharge of firework

0 (0.00)

Leiomyosarcoma

0 (0.00)

Colitis, primary sclerosing, strict definition

0.30 [-0.24, 0.84]

Other orthopaedic follow-up care

9 (0.26)

Disorders of multiple cranial nerves

0 (0.00)

Murder, homicide, or other assault by rifle, shotgun and larger firearm discharge

0 (0.00)

Osteopathy in diseases classified elsewhere

0.63 [-0.19, 1.45]

Other disorders of middle ear and mastoid in diseases classified elsewhere

Motor disorders, excluding more controls

0.68 [-0.18, 1.55]

Lichenoid drug reaction

0.09 [-0.37, 0.55]

Congenital glaucoma

0 (0.00)

Benign neoplasm: Lymph nodes

0.03 [-0.55, 0.61]

Cerebral arteritis

0 (0.00)

-0.19 [-0.59, 0.22]

Tumor necrosis factor alpha inhibitors

24 (0.32)

Exposure to unspecified factor

166 (0.28)

Other fibroblastic disorders

0.20 [-0.28, 0.69]

Familial chondrocalcinosis

Occupant of heavy transport vehicle injured in other and unspecified transport accidents

Toxic erythema

0 (0.00)

-0.11 [-0.53, 0.31]

Carcinoma in situ of skin of lower limb, including hip

0 (0.00)

Dislocation, sprain and strain of joints and ligaments of shoulder girdle

30 (0.20)

Malignant neoplasm of rectosigmoid junction, excluding all cancers (controls excluding all cancers)

0 (0.00)

Superficial injury of forearm

8 (0.15)

Adrenogenital disorders

0.32 [-0.38, 1.03]

Mucopolysaccharidosis, other/unspecified

0 (0.00)

Etanercept

8 (0.22)

Benign neoplasm of mesothelial tissue

0 (0.00)

Carcinoma in situ of skin of other and unspecified parts of face

11 (0.28)

Disorders of glycosaminoglycan metabolism

Traumatic secondary and recurrent haemorrhage

Other and unspecified cicatricial alopecia

0 (0.00)

-0.26 [-0.75, 0.24]

Melanocytic naevi

62 (0.42)

Exclusions for E4_PCOS_CONSORTIUM

174 (0.28)

Amputation of toe

Obstetric and gynaecological devices associated with adverse incidents

0 (0.00)

Injury of blood vessels at wrist and hand level

0 (0.00)

Traumatic amputation of part of head

0 (0.00)

Malignant neoplasm of other and unspecified urinary organs, excluding all cancers (controls excluding all cancers)

Other rickettsioses

0 (0.00)

Other (not insulin) diabetes medications

215 (0.26)

Crohn disease (strict definition, require KELA)

Non-follicular lymphoma, hilmo, excluding all cancers

20 (0.42)

0.35 [-0.23, 0.93]

Poisoning by and exposure to other and unspecified chemicals and noxious substances, undetermined intent

Linear scleroderma

0 (0.00)

Assault by blunt object

0 (0.00)

Pedestrian injured in collision with other nonmotor vehicle

0 (0.00)

Injury of blood vessels at ankle and foot level

0 (0.00)

Disorder of carbohydrate metabolism, other/unspecified

0 (0.00)

-0.12 [-0.56, 0.31]

Common variable immunodeficiency with autoantibodies to B- or T-cells

0 (0.00)

Substance abuse, excluding more controls

67 (0.20)

0.06 [-0.16, 0.29]

Neonatal jaundice due to drugs or toxins transmitted from mother or given to newborn

Pseudosarcomatous fibromatosis

0 (0.00)

Benign neoplasm of colon, rectum, anus and anal canal

109 (0.35)

Unspecified pneumoconiosis

0 (0.00)

Carcinoma in situ of endometrium

0.26 [-0.25, 0.78]

Soft tissue disorders in diseases classified elsewhere

Colitis due to radiation

0 (0.00)

Congenital malformation of vitreous humour

0 (0.00)

Benign neoplasm: Carotid body

0 (0.00)

-0.16 [-0.59, 0.28]

Sphingolipidosis, other/unspecified

0 (0.00)

Chromium deficiency

Carcinoid syndrome

-0.30 [-1.18, 0.59]

Pedestrian injured in other and unspecified transport accidents

Eosinophilia

Ependymoma, excluding all cancers (controls excluding all cancers)

0 (0.00)

-0.19 [-0.61, 0.23]

Dysplastic lesion of the vulva of unknown severity

0 (0.00)

0.06 [-0.38, 0.51]

Mastocytosis

0 (0.00)

0.62 [-0.32, 1.57]

Sunburn

0 (0.00)

0.49 [0.02, 0.95]

Wrist or foot drop (acquired)

Acetic acid derivatives and related substances

322 (0.27)

Traumatic spondylopathy

0 (0.00)

0.09 [-0.38, 0.57]

Open wound of shoulder and upper arm

Autonomic dysreflexia

Benign neoplasm: Central nervous system, other parts/unspecified

0 (0.00)

Dental pulpitis 2, only avohilmo

655 (0.24)

Exposure to high-pressure jet

0 (0.00)

Profound mental retardation

Colon adenocarcinoma, excluding all cancers (controls excluding all cancers)

13 (0.23)

0.09 [-0.40, 0.58]

Benign neoplasm of eye and adnexa

1168 (30.32)

Benign neoplasm: Vertebral column

0 (0.00)

Other symptoms and signs involving the digestive system and abdomen

29 (0.33)

Systemic lupus erythematosus

Malignant neoplasm of penis

0 (0.00)

Benign neoplasm: Heart

0 (0.00)

Psoas tendinitis

0 (0.00)

0.00 [-0.57, 0.58]

Hyperkinetic disorders, excluding more controls

9 (0.14)

0.14 [-0.30, 0.58]

Other disorders of bone development and growth

0 (0.00)

Conductive and sensorineural hearing loss

170 (0.33)

Use of trihexyphenidyl

0 (0.00)

73 (0.21)

Care involving dialysis

12 (0.28)

Benign neoplasm of other and ill-defined parts of digestive system

32 (0.38)

Use of dimethyl fumarate

Other and unspecified injuries of lower leg

8 (0.19)

ILD medications: immunosuppressive drugs

118 (0.33)

Pedal cyclist injured in collision with train or tram

0 (0.00)

Ophthalmic devices associated with adverse incidents

0 (0.00)

Other symptoms and signs involving general sensations and perceptions

Disorders of muscle in diseases classified elsewhere

0 (0.00)

Disorders of glycine metabolism

0 (0.00)

Clefts and syndromes for tooth agenesis exclusion, including avohilmo

Pemphigus vulgaris

0 (0.00)

-0.25 [-0.73, 0.22]

Drug-induced autoimmune haemolytic anaemia

0 (0.00)

Poikiloderma of Civatte

0.21 [-0.25, 0.68]

Sequelae of injuries of neck and trunk

Malignant neoplasm, wide definition for exclusion, excluding all cancers (controls excluding all cancers)

395 (0.31)

Melanocytic naevi of lip

Otitis media in diseases classified elsewhere

0 (0.00)

Other acantholytic disorders

0 (0.00)

0.00 [-0.42, 0.42]

Toxic myoneural disorders

0 (0.00)

Early syphilis

0 (0.00)

0.75 [-0.12, 1.62]

Short stature, not elsewhere classified

Disease of hard tissues of teeth, NOS

Chronic myeloid leukaemia

0 (0.00)

Use of eye-antiallergens (taken as indicator of allergic/atopic conjunctivitis)

125 (0.41)

Other and unspecified water transport accidents

0 (0.00)

0.65 [-0.06, 1.36]

Neglect and abandonment

Inguinal of femoral hernia, unilateral

5 (0.23)

Kaposi sarcoma, excluding all cancers (controls excluding all cancers)

0 (0.00)

-0.08 [-0.45, 0.28]

Malignant neoplasm of other and unspecified parts of biliary tract, excluding all cancers (controls excluding all cancers)

0 (0.00)

Any gastric operation

605 (0.28)

Oher contracture of tendon (sheath)

0.09 [-0.44, 0.62]

Open bite that required surgery (Lefort1 or BSSRO)

0 (0.00)

-0.16 [-0.74, 0.43]

Duodenal ulcer - Acute with haemorrhage, drug-induced

0 (0.00)

-0.14 [-0.50, 0.23]

Narcolepsy and cataplexy

0 (0.00)

0.07 [-0.54, 0.68]

Abnormal findings on diagnostic imaging and in function studies, without diagnosis

109 (0.33)

Ependymoma

0 (0.00)

Peripheral arterial reconstruction

20 (0.25)

Malignant cancer of tonsil and base of tongue, excluding all cancers (controls excluding all cancers)

0.39 [-0.85, 1.62]

Injury of muscle and tendon at wrist and hand level

14 (0.20)

Abnormal findings in nipple discharge synovial fluid wound secretions

Injury of muscle and tendon at lower leg level

31 (0.41)

Benign neoplasm: Bone and articular cartilage, unspecified

0 (0.00)

Conditions involving the integument and temperature regulation of fetus and newborn

0 (0.00)

African trypanosomiasis

Disorders of other visual pathways

0 (0.00)

Other leukaemias of specified cell type

0 (0.00)

Injury of blood vessels at abdomen, lower back and pelvis level

Secondary malignant neoplasm of other and unspecified sites

Dialysis, with operation codes

17 (0.27)

Disorders of peritoneum in infectious diseases classified elsewhere

0 (0.00)

Other hyperalimentation

0.11 [-0.29, 0.51]

Fasciculation

0 (0.00)

Urticaria due to cold and heat

-0.08 [-0.86, 0.71]

Failure in dosage during surgical and medical care

0 (0.00)

Irritant contact dermatitis due to drugs in contact with skin

0 (0.00)

Collagenous colitis

18 (0.39)

Benign neoplasm: Pineal gland

Malignant neoplasm of digestive organs

43 (0.23)

Neuroendocrine tumor and carcinoma of small intestine

0 (0.00)

Hyperinsulinism NOS, drug-induced

Carcinoma in situ of lip, oral cavity and pharynx

0 (0.00)

Benign neoplasm: Bladder

Procedures for purposes other than remedying health state

Benign neoplasm: Connective and other soft tissue of head, face and neck

5 (0.28)

Benign neoplasm: Pluriglandular involvement

0 (0.00)

Dengue fever [classical dengue]

0 (0.00)

-0.27 [-0.70, 0.15]

Malignant neoplasm of oral cavity, excluding all cancers (controls excluding all cancers)

7 (0.25)

-0.12 [-0.87, 0.63]

Injury of muscle and tendon at neck level

Disorder of visual pathways, unspecified

0 (0.00)

0.10 [-0.29, 0.48]

Benign neoplasm: Renal pelvis

-0.04 [-0.40, 0.32]

Unspecified privation

14 (0.25)

Other and unspecified hypertrophic disorders of skin

0 (0.00)

0.05 [-0.68, 0.79]

Retained (old) foreign body following penetrating wound of orbit

0 (0.00)

Burn and corrosion, body region unspecified

0 (0.00)

Other and unspecified syphilis

0 (0.00)

0.06 [-0.47, 0.60]

Unspecified protein-energy malnutrition

-0.22 [-0.82, 0.38]

Panniculitis, unspecified

0 (0.00)

0.14 [-0.45, 0.72]

Problems related to education and literacy

Disorders of conjunctiva

285 (0.59)

Other degenerative disorders of globe

0 (0.00)

L01XA Platinum compounds

Diving or jumping into water causing injury other than drowning or submersion

0 (0.00)

Adult respiratory distress syndrome

0 (0.00)

0.02 [-0.59, 0.62]

Photocontact dermatitis [berloque dermatitis]

0 (0.00)

Motor- or nonmotor-vehicle accident in traffic area

Dislocation, sprain and strain of joints and ligaments of elbow

6 (0.16)

Acute alcohol intoxication ICD-9

0 (0.00)

Fungal Sepsis

6 (0.24)

Ulcerative colitis (strict definition, require KELA)

Abnormal results of function studies

9 (0.20)

Strabismus

55 (0.40)

Complications following myocardial infarction

0 (0.00)

0.89 [-0.42, 2.21]

Injuries to the hip and thigh

72 (0.28)

Exposure to uncontrolled fire, not in building or structure

0 (0.00)

Acquired epidermolysis bullosa

0 (0.00)

Mucinosis of skin

In situ neoplasms

59 (0.33)

Certain conditions originating in the perinatal period

7 (0.12)

Pacemaker

45 (0.29)

Disease of thymus, other/unspecified

0 (0.00)

0.27 [-0.16, 0.70]

Dislocation, sprain and strain of joints and ligaments at wrist and hand level

27 (0.18)

Complications of anaesthesia during labour and delivery

0 (0.00)

0.09 [-0.36, 0.53]

Benign neoplasm: Cranial nerves

Inhalation of gastric contents

Kissing spine

-0.24 [-0.66, 0.19]

Neurological diseases

574 (0.28)

Hypopituitarism after medical therapy

0 (0.00)

Dental caries 1, only avohilmo

602 (0.25)

Necrotizing enterocolitis of fetus and newborn

0 (0.00)

Disorders of amino-acid transport

0 (0.00)

0.10 [-0.26, 0.47]

Abscess of spleen

0 (0.00)

Arthropathy in ulcerative colitis

-0.17 [-0.68, 0.35]

Complications of surgical and medical care, not elsewhere classified

179 (0.30)

Other transitory neonatal endocrine disorders

Use of tropatepine

Airway disease due to specific organic dust

0 (0.00)

0.04 [-0.40, 0.48]

Traumatic subcutaneous emphysema

Specific personality disorders

32 (0.25)

Benign neoplasm: Colon

88 (0.35)

Carcinoma in situ of uteri, other/unspecified

0 (0.00)

Demyelinating diseases of the central nervous system

11 (0.23)

Brain astrocytoma, excluding all cancers (controls excluding all cancers)

0 (0.00)

-0.18 [-0.71, 0.34]

Other benign neoplasm of uterus: Corpus uteri

0 (0.00)

DVT of lower extremities and pulmonary embolism

55 (0.26)

Other and unspecified thalassaemias

0 (0.00)

Malignant neoplasm of prostate, excluding all cancers (controls excluding all cancers)

64 (0.29)

-0.02 [-0.31, 0.28]

116

Livedoid vasculitis

0 (0.00)

0.58 [-0.06, 1.23]

Hip and thigh

0 (0.00)

Melanoma in situ of ear and external auricular canal

0 (0.00)

Parodontitis

141 (0.27)

Malignant neoplasm of other and unspecified female genital organs

0 (0.00)

Other and unspecified primary disorders of muscles

-0.36 [-1.09, 0.37]

Use of tolcapone

0 (0.00)

Carcinoma in situ of oesophagus

Exposure to other and unspecified inanimate mechanical forces

6 (0.15)

Ethmoidectomy

15 (0.23)

Benign neoplasm: Connective and other soft tissue of thorax

Foreign body or object entering through skin

5 (0.14)

Behçet disease

0 (0.00)

0.11 [-0.36, 0.57]

Sequelae of complication of pregnancy, childbirth and the puerperium

0 (0.00)

Foreign object accidentally left in body during surgical and medical care

Respiratory tuberculosis, confirmed and not-confirmed

8 (0.23)

Unspecified visual impairment (binocular)

7 (0.41)

ILD medications: pirfenidone

0 (0.00)

Fat embolism (traumatic)

Other operation for atrial fibrillation

Other specified disorders of skin and subcutaneous tissue in diseases classified elsewhere

0 (0.00)

Hirsprung

0 (0.00)

Convalescence

6 (0.18)

Complications of anaesthesia during the puerperium

0 (0.00)

-0.14 [-0.68, 0.40]

Acute disseminated encephalitis/encephalomyelitis, drug-induced

Postdysenteric arthropathy

0.27 [-0.26, 0.81]

Certain infectious and parasitic diseases

440 (0.26)

Extracorporeal dialysis

9 (0.27)

Bilateral visual impairment (ICD-8)

Ectopic hormone secretion, not elsewhere classified

0 (0.00)

Unspecified jaundice

Other behavioural and emotional disorders with onset usually occurring in childhood and adolescence

Malignant neoplasm of anus and anal canal, excluding all cancers (controls excluding all cancers)

-0.19 [-0.80, 0.41]

Onychogryphosis

0 (0.00)

-0.19 [-0.79, 0.41]

Open wound of neck

0 (0.00)

Calcific aortic valvular stenosis

36 (0.26)

Pemphigus foliaceus

0 (0.00)

Inguinal or femoral hernia, bilateral

14 (0.26)

Malignant neoplasm of palate, excluding all cancers (controls excluding all cancers)

Benign neoplasm: Pluriglandular involvement

0 (0.00)

Testicular dysfunction

7 (0.28)

Genitourinary diseases

773 (0.26)

Family history of other specific disorders

Abnormal pulmonary venous return

0 (0.00)

0.32 [-0.06, 0.69]

Megavitamin-B6 syndrome

0 (0.00)

Family history of tobacco abuse

Dermatopolymyositis, unspecified

-0.09 [-0.67, 0.48]

Spotted fever [tick-borne rickettsioses]

0 (0.00)

Benign neoplasm: Scrotum

0 (0.00)

-0.06 [-0.49, 0.37]

Neuronal ceroid lipofuscinosis

0 (0.00)

Copper deficiency

0 (0.00)

Cardiomyopathy due to drugs and other external agents

0.14 [-0.22, 0.51]

Use of biperiden

Malignant neoplasms of independent (primary) multiple sites

0 (0.00)

Burkitt lymphoma, excluding all cancers (controls excluding all cancers)

0 (0.00)

Marfan's syndrome

0 (0.00)

0.03 [-0.48, 0.54]

Calcaneal spur

0 (0.00)

-0.01 [-0.97, 0.96]

Rifle, shotgun and larger firearm discharge, undetermined intent

0 (0.00)

Malignant neoplasm of spinal cord, cranial nerves and other parts of central nervous system, excluding all cancers (controls excluding all cancers)

0 (0.00)

0.85 [-0.14, 1.84]

Monoamine oxidase A inhibitors

16 (0.25)

N06DA Anticholinesterases

55 (0.35)

Wilms' tumor

-0.14 [-0.67, 0.38]

Persons encountering health services in other circumstances, wide

271 (0.26)

Glaucoma secondary to other eye disorders

11 (0.40)

Mental and behavioural disorders due to tobacco

13 (0.29)

General- and plastic-surgery devices associated with adverse incidents

0 (0.00)

Other benign neoplasm of uterus: Cervix uteri

Intentional self-harm by explosive material

Other and unspecified vascular occlusions

11 (0.23)

Enterobiasis

0.21 [-0.36, 0.78]

Constitutional tall stature

Kaposi sarcoma

0 (0.00)

ILD, hospital admissions

20 (0.29)

Benign neoplasm: Extrahepatic bile ducts

0 (0.00)

Burns and corrosions

16 (0.22)

Nosocomial condition (hospital)

0 (0.00)

Use of natalizumab

Lethal midline granuloma

0 (0.00)

Colectomy operation

19 (0.24)

Use of etilevodopa decarboxylase inhibitor

Lack of expected normal physiological development

Fibrosis and sclerosis of liver

0 (0.00)

Congenital malformations of trachea and bronchus

-0.08 [-0.75, 0.59]

Protrusioacetabuli

0 (0.00)

Necrotizing fasciitis

0 (0.00)

-0.20 [-0.76, 0.35]

Complications of anaesthesia during pregnancy

0 (0.00)

0.03 [-0.37, 0.44]

Chronic thyroiditis

0 (0.00)

0.42 [-0.13, 0.97]

Benign neoplasm: Endocrine pancreas

GI-bleeding

47 (0.29)

Other specified acquired deformities of limbs

0 (0.00)

0.38 [-0.20, 0.96]

Nocardiosis

0 (0.00)

Interstitial emphysema and related conditions originating in the perinatal period

-0.13 [-0.55, 0.30]

Drug phototoxic response

0 (0.00)

Other/unspecified mastoiditis and related conditions

0 (0.00)

-0.13 [-1.00, 0.74]

Benign neoplasm: Skin of lip

Other abnormalities of plasma proteins

0 (0.00)

Melanoma of uvea

8 (0.53)

0.60 [-0.06, 1.27]

Persons encountering health services for examination and investigation

745 (0.27)

Frontotemporal dementia, wide, incl. Pick's disease

0 (0.00)

Dependence on enabling machines and devices, not elsewhere classified

0 (0.00)

Acute hepatitis A

0 (0.00)

-0.26 [-0.90, 0.39]

Hypersecretion of calcitonin

0 (0.00)

Unspecified fall

75 (0.29)

Benign neoplasm: Liver/bile ducts

Gangrene, not elsewhere classified

Type 2 diabetes

244 (0.26)

Melanoma in situ, other sites/unspecified

Persons encountering health services in circumstances related to reproduction

229 (0.20)

Diagnoses used for exclusion with ILD

44 (0.34)

Diastrofic dysplasy

0 (0.00)

Duodenal ulcer - Unspecified as acute or chronic, without haemorrhage or perforation, drug-induced

0.28 [-0.21, 0.77]

Acquired keratosis follicularis

0 (0.00)

Drug-induced myopathy

0.54 [-0.10, 1.18]

Use of cabergoline

Benign neoplasm: Connective and other soft tissue, unspecified

Combined immunodeficiency, unspecified

0 (0.00)

Other and unspecified firearm discharge, undetermined intent

0 (0.00)

Folliculitis ulerythematosa abscedens

0 (0.00)

Relapsing panniculitis [Weber-Christian]

0 (0.00)

Melanoma in situ of scalp and neck

0 (0.00)

Iliac crest spur

0 (0.00)

Scleritis and episcleritis

23 (0.65)

Other CVD (FINNGEN)

25 (0.32)

Drug-induced fever

0 (0.00)

Gangrene and necrosis of lung

0 (0.00)

Other inherited muscular atrophy

Injury of intra-abdominal organs

Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue

0.14 [-0.88, 1.15]

Glycogen storage disease

0 (0.00)

Severe visual impairment, binocular

-0.13 [-0.69, 0.44]

Carcinoma in situ of vulva

0.29 [-0.31, 0.89]

Leiomyoma of uterus

132 (0.30)

Coccidioidomycosis

0 (0.00)

Acné excoriée

0 (0.00)

Carcinoma in situ, eye

Poisoning by medicine, drug-induced

Contact with and exposure to communicable diseases

39 (0.22)

Malignant neoplasm of endocrine gland

7 (0.18)

Malignant neoplasm of testis, excluding all cancers (controls excluding all cancers)

-0.15 [-0.80, 0.50]

Pulmonary haemorrhage originating in the perinatal period

Persons with potential health hazards related to communicable diseases

47 (0.22)

Other and unspecified intracranial injuries

7 (0.30)

Asthma (mode)

186 (0.32)

Malignant neoplasm of breast, HER2-negative, excluding all cancers (controls excluding all cancers)

80 (0.31)

Convulsions of newborn

Other abnormal findings of blood chemistry

11 (0.40)

Contact urticaria

0 (0.00)

0.15 [-0.34, 0.65]

L02BA Anti-estrogens

25 (0.31)

Sequelae of injuries of upper limb

8 (0.15)

Presence of other devices

44 (0.38)

Conduct disorder

Phlebitis and thrombophlebitis of other deep vessels of lower extremities, drug-induced

0 (0.00)

0.11 [-0.32, 0.53]

Plasmodium vivax malaria

0 (0.00)

Malignant neoplasm of gallbladder, excluding all cancers (controls excluding all cancers)

0 (0.00)

Neurofibromatosis, type 2

0.10 [-0.32, 0.52]

Exposure to ignition or melting of other clothing and apparel

0 (0.00)

Toxic liver disease with chronic active hepatitis, drug-induced

Other neonatal haemorrhages

0 (0.00)

Primary thrombophilia

Amyloidosis

Testicular hyperfunction

0 (0.00)

Dental caries 1 and operation codes

545 (0.25)

Other conditions originating in the perinatal period

Primary ovarian failure

-0.42 [-1.52, 0.68]

Carcinoma in situ of anus and anal canal

0 (0.00)

Methaemoglobinaemia

0 (0.00)

Toxic encephalopathy

0 (0.00)

0.08 [-0.37, 0.54]

Thyrotoxicosis, other and/or unspecified

28 (0.28)

Benign lipomatous neoplasm of skin and subcutaneous tissue of other and unspecified sites

0 (0.00)

0.58 [-0.54, 1.70]

Transitory endocrine and metabolic disorders specific to fetus and newborn

Malignant neoplasm of breast, excluding all cancers (controls excluding all cancers)

80 (0.31)

0.06 [-0.18, 0.30]

Cytomegaloviral hepatitis

-0.03 [-0.51, 0.45]

Malignant neoplasm of oropharyng

0 (0.00)

Other acute viral hepatitis

Cluster headache, wide,, including avohilmo

8 (0.25)

Acute lymphocytic leukaemia, excluding all cancers (controls excluding all cancers)

0 (0.00)

0.14 [-0.34, 0.63]

Diffuse large B-cell lymphoma, excluding all cancers (controls excluding all cancers)

0.47 [-0.20, 1.13]

Craniosynostosis EXCLUDE syndromes

0 (0.00)

0.25 [-0.16, 0.66]

Duodenal ulcer - Acute without haemorrhage or perforation, drug-induced

0 (0.00)

Intentional self-harm by unspecified means

0 (0.00)

Mood disorders, excluding more controls

174 (0.25)

Other conditions of integument specific to fetus and newborn

0 (0.00)

Open wound of head

69 (0.24)

Other/unspecified reactive arthropathies

External causes of morbidity and mortality

666 (0.25)

Unspecified renal colic

0 (0.00)

0.45 [-0.28, 1.18]

Familial dysautonomia

Molybdenum deficiency, drug-induced

Malignant neoplasm, without specification of site, excluding all cancers (controls excluding all cancers)

7 (0.23)

Liposarcoma, excluding all cancers (controls excluding all cancers)

0.35 [-0.26, 0.96]

Contact with other specified venomous animals

0 (0.00)

Injury of muscle and tendon at forearm level

Early lumbar disc prolapse operation

5 (0.08)

Other birth injuries

0 (0.00)

Nail disorders in diseases classified elsewhere

0 (0.00)

Benign neoplasm: Mesothelial tissue of peritoneum

0 (0.00)

Malignant neoplasm of pyriform sinus, excluding all cancers (controls excluding all cancers)

0 (0.00)

Manganese deficiency

Alopecia mucinosa, drug-induced

0 (0.00)

Polytrichia

Somnolence, stupor and coma

Chloasma

0 (0.00)

0.13 [-0.33, 0.58]

Actinic granuloma

0 (0.00)

Psoriatic and enteropathic arthropathies

23 (0.36)

Failure and rejection of transplanted organs and tissues

Adenocarcinoma and ductal carcinoma of pancreas, excluding all cancers (controls excluding all cancers)

0.16 [-1.34, 1.67]

Cleft hard palate NOS

0.02 [-0.44, 0.49]

Secondary malignant neoplasm of respiratory and digestive organs, excluding all cancers (controls excluding all cancers)

22 (0.27)

Alcoholic myopathy

0 (0.00)

Maple-syrup-urine disease

0 (0.00)

Correction of physiology of bite - demanding therapy visit

11 (0.28)

Congenital syphilis

0 (0.00)

Colitis, primary sclerosing

Contracture of muscle

0 (0.00)

-0.02 [-0.49, 0.45]

Common variable immunodeficiency with predominant abnormalities of T-cell numbers and function

0 (0.00)

Other/unspecified seropositive rheumatoid arthritis (ICD-10)

47 (0.36)

Drug-induced gout

-0.02 [-0.46, 0.41]

Other specified metabolic disorders, drug-induced

Chronic postrheumatic arthropathy [Jaccoud]

Psychiatric diseases

377 (0.25)

Obesity and other hyperalimentation

92 (0.27)

Malignant neoplasm of peripheral nerves and autonomic nervous system

0 (0.00)

Birth injury to skeleton

0 (0.00)

Carcinoma in situ of skin of upper limb, including shoulder

6 (0.32)

Acquired hypertrichosis lanuginosa

Malignant neoplasm of other and unspecified parts of mouth, excluding all cancers (controls excluding all cancers)

Arenaviral haemorrhagic fever

0 (0.00)

Use of other anti-dementia drugs, combinations

Appendicitis, broad definition

Carcinoma in situ of cervix uteri, endocervix

0 (0.00)

Use of selegiline

Benign neoplasm: Vagina

5 (0.31)

Assault by hanging, strangulation and suffocation

Encephalopathy

0 (0.00)

-0.12 [-0.74, 0.49]

Oral corticosteroids

254 (0.34)

Chlamydia psittaci infection

0 (0.00)

Disorders of adult personality and behaviour

39 (0.25)

Metabolic disorder, unspecified, drug-induced

Unspecified effects of radiation

0 (0.00)

Chromophobe cell carcinoma of kidney

0 (0.00)

Disorders of gallbladder, biliary tract and pancreas

170 (0.26)

Malignant neoplasm of other and ill-defined sites in the lip, oral cavity and pharynx

0 (0.00)

Pedestrian injured in collision with pedal cycle

Intrahepatic Cholestasis of Pregnancy (ICP) , excluding more controls

-0.19 [-0.56, 0.19]

Telogen effluvium

0 (0.00)

0.01 [-0.45, 0.47]

Drugs, medicaments and biological substances causing adverse effects in therapeutic use

12 (0.25)

Dental caries 3

565 (0.24)

Asthma-related pneumonia or sepsis

65 (0.35)

Unilateral visual impairment (ICD-8)

Myoclonus, drug-induced

0 (0.00)

Congenital absence, atresia and stenosis of large intestine

0 (0.00)

-0.09 [-0.41, 0.24]

Malignant neoplasm of placenta

Disorders of purine and pyrimidine metabolism, other/unspecified

0 (0.00)

Premenstrual syndrome

0 (0.00)

0.11 [-0.50, 0.72]

Agent resistant to penicillin and related antibiotics

0 (0.00)

Other mycoses, not elsewhere classified/unspecified

0 (0.00)

0.12 [-0.44, 0.68]

Leiomyosarcoma, excluding all cancers (controls excluding all cancers)

0 (0.00)

0.03 [-0.70, 0.75]

Radiodermatitis

0 (0.00)

-0.14 [-0.54, 0.27]

Benign neoplasm: Lip

5 (0.26)

Other drug-induced osteomalacia in adults

0 (0.00)

Chronic drug-induced interstitial lung disorders

0 (0.00)

0.14 [-0.25, 0.54]

Transitional cell carcinoma of kidney

Benign lipomatous neoplasm of skin and subcutaneous tissue of trunk

22 (0.33)

Bitten or stung by nonvenomous insect and other nonvenomous arthropods

0 (0.00)

Carcinoma in situ of anus and anal canal

0 (0.00)

Systemic sclerosis,strict definition

-0.21 [-0.76, 0.34]

Asthma, including avohilmo

252 (0.31)

Triptan medication for migraine, min. 3 purchases

71 (0.22)

Melanocytic naevi of eyelid, including canthus

Malignant neoplasm of accessory sinuses, excluding all cancers (controls excluding all cancers)

Persons with potential health hazards related to family and personal history and certain conditions influencing health status

260 (0.32)

Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism

176 (0.28)

Accidental poisoning by and exposure to pesticides

0 (0.00)

Myotonic disorders

0.21 [-0.66, 1.07]

Colour vision deficiencies

0.11 [-0.37, 0.58]

Pneumonia, organism unspecified

186 (0.26)

Nezelof syndrome

0 (0.00)

0.46 [-0.29, 1.21]

Seminoma of testis

Benign neoplasm of soft tissue of retroperitoneum and peritoneum

0 (0.00)

-0.04 [-0.72, 0.63]

Defect, injury or illness of neck

Disturbances of skin sensation

40 (0.28)

Use of ocrelizumab

Polyp of middle ear

0 (0.00)

-0.05 [-0.43, 0.33]

Other chronic figurate erythema

0 (0.00)

Use of edaravone

Benign neoplasm: Ill-defined sites within the digestive system

-0.23 [-1.17, 0.71]

Convulsions, not elsewhere classified

28 (0.21)

Benign neoplasm: Mesothelial tissue of other sites/unspecified

0 (0.00)

Monocytic leukaemia

0 (0.00)

-0.54 [-1.16, 0.08]

Other early complications of trauma

80 (0.42)

Carcinoma in situ, thyroid and other endocrine glands

0 (0.00)

Alzheimer’s disease (Early onset), excluding more controls

-0.55 [-1.63, 0.52]

Melanocytic naevi of scalp and neck

Other abnormal findings in urine

Carcinoma in situ of other and unspecified digestive organs

0 (0.00)

Polyneuropathy due to other toxic agents

0 (0.00)

Postinfectious hypothyroidism

0.16 [-0.41, 0.73]

Acne vulgaris

8 (0.16)

Tic and related disorders

0 (0.00)

0.75 [0.05, 1.46]

Injury of nerves at hip and thigh level

0 (0.00)

Benign neoplasm: Ill-defined sites within the digestive system

IPHG Phlebitis and thrombophlebitis of intracranial venous sinuses

0 (0.00)

Air embolism (traumatic)

Carcinoma in situ of rectum

0 (0.00)

-0.24 [-1.05, 0.56]

Sequelae of external causes of morbidity and mortality

24 (0.20)

Carcinoma in situ, other and unspecified urinary organs

0 (0.00)

Injury of unspecified body region

Anuria and oliguria

Total colectomy operation

6 (0.22)

Malignant neoplasm of breast, HER2-negative

78 (0.32)

Benign neoplasm: Female genital organ, unspecified

-0.11 [-0.64, 0.41]

Handgun discharge

0 (0.00)

Crohn disease

20 (0.29)

Bilateral

0 (0.00)

Disorders of thyroid, IBD co-morbidities

51 (0.34)

Burkitt lymphoma

0 (0.00)

Lichen ruber moniliformis

0 (0.00)

Exposure to excessive natural heat

0 (0.00)

Drug-induced systemic lupus erythematosus

0.37 [-0.28, 1.02]

Endovascular or surgical operations to intracerebral aneurysms

10 (0.28)

Tetanus

0 (0.00)

Disorders of muscle tone of newborn

-0.17 [-0.63, 0.28]

Sequelae of poliomyelitis

0.11 [-0.53, 0.74]

Endometriosis in cutaneous scar

0 (0.00)

-0.02 [-0.46, 0.42]

Disorders of plasma-protein metabolism, not elsewhere classified, drug-induced

0 (0.00)

Antibody deficiency with near-normal immunoglobulins or with hyperimmunoglobulinaemia

Type 2 diabetes, definitions combined, including avohilmo

237 (0.26)

Exposure to excessive cold of man-made origin

0 (0.00)

Surgical and other medical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure

94 (0.29)

Hypertrophy of bone

0 (0.00)

0.05 [-0.44, 0.54]

Embolism and thrombosis of abdominal aorta

0 (0.00)

-0.06 [-0.53, 0.41]

Other benign neoplasm of uterus: Cervix uteri

0.22 [-0.30, 0.74]

Toxic liver disease with hepatitis, not elsewhere classified, drug-induced

Other sudden death, cause unknown

Parodontitis, under 40 years

5 (0.09)

Use of metixene

0 (0.00)

Congenital ectropion

0 (0.00)

Benign neoplasm: Mesothelial tissue of peritoneum

0 (0.00)

Acquired ichthyosis

0 (0.00)

Coxibs

339 (0.28)

Ascariasis

Chromophobe cell carcinoma of kidney, excluding all cancers (controls excluding all cancers)

0 (0.00)

0.07 [-0.49, 0.62]

Dipeptidyl peptidase 4 (DPP-4) inhibitors

12 (0.21)

Hypothyroidism (congenital or acquired)

190 (0.28)

Other transitory neonatal electrolyte and metabolic disturbances

Elevated erythrocyte sedimentation rate and abnormality of plasma viscosity

11 (0.26)

SLE, strict definition

Other or unspecified common variable immunodeficiency

-0.28 [-0.73, 0.18]

Malignant neoplasm of ureter

0 (0.00)

Dengue

Congenital malformation syndromes predominantly affecting facial appearance

Open wound of hip and thigh

Other injuries of upper limb, level unspecified

Deficiency of vitamin E

0 (0.00)

Benign neoplasm: Female genital organ, unspecified

Other and unspecified injuries of abdomen, lower back and pelvis

Adverse effects, not elsewhere classified

29 (0.29)

Mature T/NK-cell lymphomas, hilmo, excluding all cancers

0.26 [-0.38, 0.90]

Open wound of thorax

Benign neoplasm: Prostate

-0.08 [-0.67, 0.52]

Respiratory tuberculosis, clinically confirmed

Stevens-Johnson syndrome, drug-induced

Human immunodeficiency virus [HIV] disease resulting in other specified diseases

Other primary thrombocytopenia

0 (0.00)

0.11 [-0.37, 0.60]

Diseases of pulp and periapical tissues, including avohilmo

335 (0.25)

Infection of intervertebral disc (pyogenic)

0 (0.00)

0.29 [-0.31, 0.89]

Vasculitis limited to skin, not elsewhere classified

5 (0.24)

Degeneration of nervous system due to alcohol

0 (0.00)

Injuries to the elbow and forearm

110 (0.28)

Use of memantine

33 (0.28)

Benign neoplasm of other and unspecified female genital organs

11 (0.40)

Senility

Other perinatal digestive system disorders

0 (0.00)

Maternal care for (suspected) damage to fetus from alcohol

0 (0.00)

0.08 [-0.35, 0.52]

Bacterial meningoencephalitis and meningomyelitis

0 (0.00)

Refsum disease

0 (0.00)

Ovarian dysfunction: estrogen excess

Sequelae of hyperalimentation

0 (0.00)

0.09 [-0.26, 0.43]

Inhalation and ingestion of other objects causing obstruction of respiratory tract

Carcinoma in situ of other/unspecified female genital organs

0 (0.00)

Lupus erythematosus, drug-induced

0 (0.00)

Disorders of other digestive organs in diseases classified elsewhere

0 (0.00)

Hereditary nephropathy, not elsewhere classified

-0.58 [-1.18, 0.02]

Murder, homicide, or other assault by handgun discharge

0 (0.00)

Injury of blood vessels of thorax

0 (0.00)

Ischaemic Stroke, excluding all haemorrhages

88 (0.27)

Diseases of the ear and mastoid process

341 (0.29)

Smallpox

0 (0.00)

Laparoscopic right hemicolectomy

5 (0.16)

Reduction defects of upper limb

0 (0.00)

-0.37 [-0.85, 0.10]

Carcinoma in situ of other/unspecified male genital organs

0 (0.00)

Tuberculosis of other organs

0 (0.00)

Malignant neoplasm of trachea, excluding all cancers (controls excluding all cancers)

0 (0.00)

Personal history of allergy to analgesic agent

Secondary parkinsonism, excluding more controls

5 (0.23)

-0.26 [-0.86, 0.35]

Unspecified nephritic syndrome, drug-induced

Waldenstrom macroglobulinemia, lymphoplasmacytic lymphoma, excluding all cancers (controls excluding all cancers)

0 (0.00)

-0.30 [-1.07, 0.47]

Vitamin A deficiency

0 (0.00)

-0.16 [-0.72, 0.40]

Aortic valve malfunction, age under 60 years

10 (0.21)

Carcinoma in situ of vagina

0 (0.00)

Carcinoma in situ of bronchus and lung

0 (0.00)

Anencephaly and similar malformations

Secondary and unspecified malignant neoplasm of lymph nodes, excluding all cancers (controls excluding all cancers)

18 (0.25)

Phantom limb syndrome with pain

0 (0.00)

0.27 [-0.20, 0.75]

Malignant neoplasm of other and ill-defined digestive organs

0 (0.00)

Medicines for HER+ breast cancer

53 (0.31)

Right ventricular outflow tract obstruction

-1.00 [-3.33, 1.33]

Disorders of accommodation

0 (0.00)

Toxic effect of other noxious substances eaten as food

0 (0.00)

Secondary thrombocytopenia, drug-induced

0 (0.00)

Injury of urinary and pelvic organs

Disorder of amino-acid metabolism, other/unspecified

0 (0.00)

Acne tropica

0 (0.00)

Female pelvic inflammatory disorders in diseases classified elsewhere

0.23 [-0.30, 0.76]

Carcinoma in situ of bronchus and lung

0 (0.00)

Other disorders of amino-acid metabolism

0 (0.00)

0.25 [-0.31, 0.82]

Type of accident

Brain glioblastoma and astrocytoma, excluding all cancers (controls excluding all cancers)

0 (0.00)

-0.30 [-1.05, 0.46]

Arthropod-borne viral fevers and viral haemorrhagic fevers

9 (0.18)

Bitten or struck by other mammals

9 (0.15)

Carcinoma in situ of skin of eyelid, including canthus

0 (0.00)

Benign neoplasm: Skin of upper limb, including shoulder

Benign neoplasm: Trachea

0 (0.00)

Molybdenum deficiency

Undefined dementia

9 (0.13)

Parasetamol

597 (0.28)

Disorders of branched-chain amino-acid metabolism and fatty-acid metabolism

0 (0.00)

Internuclear ophthalmoplegia

0 (0.00)

0.04 [-0.36, 0.44]

Benign neoplasm: Mesothelial tissue of pleura

0 (0.00)

Haematosalpinx/Haematoma of broad ligament

0 (0.00)

0.31 [-0.15, 0.77]

Hypervitaminosis D

Beau lines

Malignant neoplasm of oesophagus, excluding all cancers (controls excluding all cancers)

-0.12 [-0.80, 0.56]

Non-selective monoamine reuptake inhibitors

69 (0.33)

Fissure and fistula of anal and rectal regions

47 (0.36)

Strongyloidiasis

Open wound of abdomen, lower back and pelvis

Presence of other functional implants

122 (0.36)

Pedestrian injured in collision with two- or three-wheeled motor vehicle

0 (0.00)

Benign neoplasm: Ascending colon

16 (0.27)

Carcinoma in situ of oral cavity

0 (0.00)

0.04 [-0.34, 0.42]

Macular hole, drug-induced

0 (0.00)

Afelimomab

Myocardial infarction

85 (0.23)

Postprocedural disorders of ear and mastoid process, not elsewhere classified

0.49 [-0.18, 1.15]

Reactions and intoxications due to drugs administered to fetus and newborn

Tramadol

186 (0.37)

Malignant neoplasm of hypopharynx

0 (0.00)

Abnormal weight loss

12 (0.27)

Benign neoplasm: Skin of other and unspecified parts of face

17 (0.30)

Dental invagination

0 (0.00)

Benign neoplasm: Ciliary body

Juvenile dermatomyositis

0 (0.00)

Respiratory tuberculosis, bacteriologically and histologically confirmed

Benign neoplasm: Conjunctiva

1168 (100.00)

Genetic anomalies of leukocytes

0 (0.00)

Malignant melanoma of skin, excluding all cancers (controls excluding all cancers)

31 (0.44)

0.13 [-0.30, 0.56]

Injury of blood vessels at shoulder and upper arm level

Malignant neoplasm of bone and articular cartilage of other and unspecified sites

0 (0.00)

Use of piribedil

Dental operations, only avohilmo

689 (0.25)

Injury of nerves at lower leg level

0 (0.00)

Human immunodeficiency virus [HIV] disease resulting in malignant neoplasms

Pedestrian injured in collision with heavy transport vehicle or bus

0 (0.00)

Exposure to sunlight

0 (0.00)

Drug-induced nonautoimmune haemolytic anaemia

0 (0.00)

Symptoms and signs involving the skin and subcutaneous tissue

129 (0.34)

Henoch-Schönlein purpura nephritis (HSPN)

0 (0.00)

-0.55 [-1.13, 0.03]

Disorders of plasma-protein metabolism, not elsewhere classified

0 (0.00)

-0.27 [-1.04, 0.49]

Injury of nerves and lumbar spinal cord at abdomen, lower back and pelvis level

0 (0.00)

Changes in corneal membranes

0 (0.00)

-0.29 [-0.75, 0.16]

Parodontitis and operation codes

136 (0.28)

Choroidal degeneration

0 (0.00)

Ovarian dysfunction, other/unspecified

-0.07 [-0.75, 0.61]

Lung transplant status

0.03 [-0.58, 0.64]

Unspecified urinary incontinence

7 (0.15)

Benign neoplasm: Connective and other soft tissue of pelvis

Actinomycosis

0 (0.00)

1.00 [-0.07, 2.07]

Other symptoms and signs involving the nervous and musculoskeletal systems

69 (0.31)

Human immunodeficiency virus [HIV] disease

Miliaria rubra

Chronic suppurative otitis media, including avohilmo

9 (0.20)

Colorectal adenocarcinoma, excluding all cancers (controls excluding all cancers)

23 (0.25)

-0.11 [-0.52, 0.29]

Hypoplasia of dental enamel, including avohilmo

-0.49 [-1.26, 0.28]

Morphin

Periodontosis

0 (0.00)

Congenital pneumonia

5-aminosalicylic acid

30 (0.25)

Arthropathic psoriasis

19 (0.33)

Neurofibromatosis, type 1

-0.21 [-0.76, 0.34]

Fracture of upper limb, level unspecified

0 (0.00)

Hypospadias

0 (0.00)

0.60 [-0.04, 1.25]

Contaminated medical or biological substances

0 (0.00)

Thyroid crisis or storm

0 (0.00)

-0.34 [-0.86, 0.17]

Endocrine, nutritional and metabolic diseases

581 (0.26)

Benign neoplasm: Spinal meninges

Pupillary membranes and other adhesions and disruptions of iris and ciliary body

0 (0.00)

0.34 [-0.10, 0.78]

Intrahepatic Cholestasis of Pregnancy (ICP) , incl. ICD-8, excluding more controls

6 (0.13)

-0.16 [-0.52, 0.20]

Malignant neoplasm of retroperitoneum and peritoneum

Other proliferative retinopathy

0 (0.00)

0.26 [-0.41, 0.93]

Taurodontism

Thiazolidinediones

Digestive system disorders of fetus and newborn

0 (0.00)

Implicit Sepsis

151 (0.34)

Haemangioma and lymphangioma, any site

18 (0.38)

Postpartum care and examination

18 (0.13)

Other psoriatic arthropathies

17 (0.32)

Foreign body in ear

Drowning to ice

0 (0.00)

Benign neoplasm: Other specified/unspecified intrathoracic organs (+ respiratory system NOS of Icd-9)

0 (0.00)

Macular pucker, drug-induced

0 (0.00)

Macular cyst, drug-induced

Nonvenereal syphilis

Noninfective disorders of pinna

0 (0.00)

-0.04 [-0.43, 0.34]

Metabolic disorder, other/unspecified

0 (0.00)

-0.34 [-0.86, 0.18]

Pityriasis lichenoides chronica

0 (0.00)

0.13 [-0.34, 0.60]

Carcinoma in situ of oesophagus

Traumatic amputation of ankle and foot

0 (0.00)

Benign neoplasm: Prostate

Benign neoplasm: Hypopharynx

0 (0.00)

Cardiovascular diseases

756 (0.27)

Adenocarcinomas of cervix, excluding all cancers (controls excluding all cancers)

0.40 [-0.29, 1.10]

Benign neoplasm: Descending colon

14 (0.40)

Acne varioliformis

0 (0.00)

-0.50 [-1.16, 0.16]

Fall on and from ladder

8 (0.20)

Benign neoplasm: Brain, unspecified

0 (0.00)

Benign lipomatous neoplasm of skin and subcutaneous tissue of head, face and neck

16 (0.44)

Benign neoplasm: Rectum/anal canal icd-9

Malignant neoplasm of rectum, excluding all cancers (controls excluding all cancers)

15 (0.24)

-0.21 [-0.61, 0.20]

Parkinson's disease, excluding more controls

15 (0.21)

Benign neoplasm: Liver

Vertiginous syndromes in diseases classified elsewhere

0 (0.00)

Mental retardation, excluding more controls

0.53 [-0.25, 1.30]

Examination and observation for other reasons

129 (0.30)

Vibratory urticaria

0 (0.00)

Atlantoaxial subluxation

0 (0.00)

0.88 [-0.62, 2.39]

Injuries to the thorax

61 (0.26)

ICD-8 DM (Sub-endpoint used for defining DM endpoints)

7 (0.26)

Mixed disorder of acid-base balance

0 (0.00)

Hypercarotenaemia

Benign neoplasm: Pituitary gland, craniopharyngeal duct

7 (0.22)

Complications of procedures, not elsewhere classified

140 (0.30)

Malignant neoplasm of renal pelvis, excluding all cancers (controls excluding all cancers)

0 (0.00)

-0.15 [-1.91, 1.62]

Other and unspecified aplastic anaemias

0 (0.00)

-0.87 [-2.78, 1.04]

Malignant neoplasm of eye, brain and central nervous system

27 (0.98)

Family history of certain disabilities and chronic diseases leading to disablement

Classical phenylketonuria

0 (0.00)

Leisure time condition

21 (0.23)

Other thrombophilia

Injury of nerves at ankle and foot level

Hepatomegaly and splenomegaly, not elsewhere classified

Unspecified drowning and submersion

0 (0.00)

Granulosa cell carcinoma of ovary

Oedema, not elsewhere classified

59 (0.36)

Post-traumatic wound infection, not elsewhere classified

Ovarian hyperstimulation (induction)

-0.25 [-0.86, 0.37]

Mandibular prognathia AND surgery (LeFortI or BSSRO)

0.26 [-0.29, 0.81]

66 (0.20)

Malignant neoplasm of vagina

0 (0.00)

Osteogenesis imperfecta

0 (0.00)

Rash and other nonspecific skin eruption

19 (0.37)

Protein-energy malnutrition of moderate and mild degree

-0.44 [-1.09, 0.21]

Adrenomedullary hyperfunction

0 (0.00)

0.29 [-0.23, 0.82]

Hirsutism, drug-induced

0 (0.00)

0.04 [-0.35, 0.44]

Secondary uncertain malignant neoplasm, excluding all cancers (controls excluding all cancers)

55 (0.27)

Frostbite with tissue necrosis

Pyoderma gangrenosum

Sulfasalazine

44 (0.28)

Benign neoplasm: Heart

0 (0.00)

0.04 [-0.40, 0.47]

Rabies

0 (0.00)

Gout, FINNGEN

33 (0.24)

Liver disorders in diseases classified elsewhere

0 (0.00)

-0.15 [-0.68, 0.39]

Exposure to other specified factors

104 (0.24)

Pneumonia due to Haemophilus influenzae

-0.45 [-1.02, 0.12]

Diffuse brain injury

Hereditary nephropathy, not elsewhere classified, drug-induced

Injuries to the shoulder and upper arm

130 (0.27)

Other misadventures during surgical and medical care

Other antidepressants

246 (0.25)

Bacterial agents resistant to antibiotics

0 (0.00)

Benign neoplasm of mouth and pharynx

21 (0.38)

Malignant neoplasm of tongue, excluding all cancers (controls excluding all cancers)

Fetal blood loss

0 (0.00)

Chondrosarcoma, excluding all cancers (controls excluding all cancers)

0 (0.00)

0.53 [-0.08, 1.14]

Intentional self-poisoning by and exposure to other and unspecified chemicals and noxious substances

21 (0.24)

Other and unspecified types of non-Hodgkin lymphoma, hilmo, excluding all cancers

9 (0.34)

0.20 [-0.45, 0.86]

Glanders and melioidosis

Apocrine sweat disorders, other sweat gland disorders

0.50 [-0.11, 1.11]

Malignant neoplasm of tongue

Benign neoplasm: Peripheral nerves and autonomic nervous system

5 (0.29)

Polyglandular hyperfunction

0 (0.00)

Vitreous prolapse

0 (0.00)

-0.25 [-0.75, 0.25]

Type 1 diabetes, strict definition, subgroup 1

6 (0.12)

Diffuse (eosinophilic) fasciitis

0 (0.00)

0.03 [-0.30, 0.37]

Malignant neoplasm of other and ill-defined sites in the respiratory system and intrathoracic organs, excluding all cancers (controls excluding all cancers)

Striking against or struck by other objects

38 (0.22)

0 (0.00)

Melanoma in situ of lip

0 (0.00)

Noninfectious colitis NAS

17 (0.24)

Pulmonary eosinophilia, not elsewhere classified

0.23 [-0.31, 0.76]

Occupational exposure to risk-factors

Diabetes medication

Other lack of coordination

Abnormalities of ear ossicles

0 (0.00)

-0.22 [-0.66, 0.22]

Septicaemia

38 (0.18)

Use of mazaticol

Butylpyrazolidines

0 (0.00)

Exclusion endpoint for supernumerary teeth

0 (0.00)

Benign neoplasm: Other parts of oropharynx

Huntington disease

Maxillary hypoplasia

0.10 [-0.35, 0.54]

Dental caries, including avohilmo

611 (0.25)

Superficial injury of hip and thigh

24 (0.32)

Schistosomiasis [bilharziasis]

Diphyllobothriasis and sparganosis

Colorectal neuroendocrine tumor and carcinoma, excluding all cancers (controls excluding all cancers)

-0.35 [-0.94, 0.23]

Other viral hepatitis

Tympanosclerosis

-0.40 [-0.90, 0.10]

Traumatic subdural haemorrhage

18 (0.26)

Tuberculosis of nervous system

0 (0.00)

Any dementia, excluding more controls

67 (0.29)

-0.18 [-0.56, 0.20]

Drug-induced obesity

0 (0.00)

-0.02 [-0.71, 0.68]

Benign neoplasm: Larynx

Disorders of puberty, all

Sweet's syndrome

0 (0.00)

Malignant neoplasm of bone and articular cartilage of limbs, excluding all cancers (controls excluding all cancers)

0 (0.00)

Immobility syndrome (paraplegic)

0 (0.00)

Keratosis follicularis et parafollicularis in cutem penetrans [Kyrle]

Congenital malformations of lung

0.08 [-0.30, 0.47]

Other disturbances of temperature regulation of newborn

Explosion of other materials

Isolated proteinuria

Diphtheria

0 (0.00)

0.25 [-0.16, 0.66]

Congenital myopathies

-0.30 [-0.75, 0.16]

Agent resistant to other and unspecified antibiotics

Use of tacrine

Hereditary choroidal dystrophy

0 (0.00)

Edwards' syndrome and Patau's syndrome

Visual disturbances in diseases classified elsewhere

0 (0.00)

COPD/asthma related infections

404 (0.24)

ILD medications

331 (0.32)

Benign neoplasm: Lower jaw bone

0 (0.00)

Petrositis

0 (0.00)

Benign neoplasm: Vertebral column

0 (0.00)

Non-small cell lung cancer, adenocarcinoma, helper endpoint

6 (0.17)

Superficial injury of ankle and foot

13 (0.20)

Traumatic subarachnoid haemorrhage

Hereditary angioödema type 2

0 (0.00)

Disorders of urea cycle metabolism

0 (0.00)

General hospital and personal-use devices associated with adverse incidents

0 (0.00)

Magnesium deficiency, drug-induced

Benign neoplasm: Lower jaw bone

0 (0.00)

0.40 [-0.18, 0.98]

Melanocytic naevi, other sites/unspecified

18 (0.42)

Golimumab

7 (0.29)

Malignant neoplasm of small intestine, excluding all cancers (controls excluding all cancers)

-0.06 [-0.81, 0.69]

Fall on and from stairs and steps

42 (0.33)

Merkel cell carcinoma of skin, excluding all cancers (controls excluding all cancers)

0 (0.00)

Psoriatic arthropathies, strict definition

0 (0.00)

Reduction defects of unspecified limb

0 (0.00)

Abnormality of white blood cells, not elsewhere classified

0 (0.00)

Spirochaetal infections, other/unspecified

11 (0.26)

Injuries to the neck

27 (0.23)

Anxiety disorders, excluding more controls

134 (0.22)

0.12 [-0.12, 0.37]

Deaf mutism, not elsewhere classified

0 (0.00)

-0.24 [-0.98, 0.51]

L04AX Other immunosuppressants

97 (0.33)

Corneal pigmentations and deposits, drug-induced

Benign neoplasm: Pharynx, unspecified

0.18 [-0.37, 0.73]

Exclusions for E4_PCOS_BROAD

23 (0.27)

Other retinal disorders in diseases classified elsewhere

0 (0.00)

-0.06 [-0.57, 0.45]

Malignant neoplasm of vagina, excluding all cancers (controls excluding all cancers)

0 (0.00)

0.04 [-0.43, 0.51]

Benign neoplasm: Connective and other soft tissue of upper limb, including shoulder

6 (0.21)

Congenital absence, atresia and stenosis of small intestine

0 (0.00)

Exposure to electric transmission lines

0 (0.00)

Follow-up examination after treatment for malignant neoplasms

15 (0.26)

Victim of lightning

IBD (strict) with PSC

0.39 [-0.16, 0.93]

Cardiac murmurs and other cardiac sounds

10 (0.18)

Otorrhagia

-0.12 [-0.83, 0.59]

Foreign body in respiratory tract

5 (0.16)

Pain, not elsewhere classified

46 (0.31)

Monoplegia

-0.35 [-1.01, 0.31]

Cystic fibrosis with pulmonary manifestations

0 (0.00)

Benign lipomatous neoplasm of skin and subcutaneous tissue of limbs

15 (0.35)

Fractures involving multiple body regions

0.07 [-0.31, 0.44]

Erythema marginatum

0 (0.00)

Headache

141 (0.35)

Anti-inflammatory and antirheumatic products, non-steroids

977 (0.24)

Symptoms and signs involving cognition, perception, emotional state and behaviour

213 (0.32)

Organic, including symptomatic, mental disorders

96 (0.30)

Malignant neoplasm, excluding all cancers (controls excluding all cancers)

395 (0.31)

0.11 [-0.18, 0.40]

Major coronary heart disease event excluding revascularizations

124 (0.25)

Carcinoma in situ of other/unspecified female genital organs

0 (0.00)

Toxic effect of corrosive substances

0 (0.00)

Motor- or nonmotor-vehicle accident, type of vehicle unspecified

0 (0.00)

Felty syndrome

0.07 [-0.45, 0.59]

Melanocytic naevi of other and unspecified parts of face

10 (0.29)

Upper arm

0 (0.00)

Benign neoplasm: Bronchus and lung

Lipid storage disorder, other/unspecified

0 (0.00)

Polyneuropathies and other disorders of the peripheral nervous system

32 (0.31)

Diabetes insipidus

0.32 [-0.68, 1.32]

Miliaria, unspecified

0 (0.00)

Other respiratory conditions originating in the perinatal period

Postimmunization arthropathy, drug-induced

Intestinal helminthiases, other/unspecified

Complications specific to multiple gestation

-0.11 [-0.66, 0.44]

Disorders of fructose metabolism

0 (0.00)

Pelvic region

0 (0.00)

Budesonide

18 (0.25)

Gastrointestinal stromal tumor and sarcoma, excluding all cancers (controls excluding all cancers)

0.13 [-0.60, 0.87]

Oesophagitis, drug-induced

0 (0.00)

0.44 [-0.11, 0.99]

Malignant neoplasm of hypopharynx, excluding all cancers (controls excluding all cancers)

0 (0.00)

0.37 [-0.38, 1.12]

Voice disturbances

43 (0.33)

Polyglandular dysfunction

-0.10 [-0.50, 0.29]

KRA_PSY_EATING, excluding more controls

7 (0.13)

0.18 [-0.50, 0.85]

Codeine

259 (0.30)

Use of profenamine

Toxic liver disease with fibrosis and cirrhosis of liver, drug-induced

0 (0.00)

Lichen planus, including avohilmo

23 (0.27)

Histoplasmosis

0 (0.00)

Moderate visual impairment, monocular

0 (0.00)

-0.20 [-0.72, 0.32]

Malignant neoplasm of other and ill-defined sites

0 (0.00)

Postpartum hemorraghe, all women as controls

31 (0.23)

-0.27 [-0.72, 0.18]

Brain medulloblastoma, excluding all cancers (controls excluding all cancers)

0 (0.00)

Malignant neoplasm of meninges, excluding all cancers (controls excluding all cancers)

0.01 [-0.49, 0.52]

Hypothermia of newborn

0 (0.00)

Malignant neoplasm of oropharynx

Foreign body in alimentary tract

6 (0.18)

Aspergillosis

0 (0.00)

0.05 [-0.64, 0.74]

Purine nucleoside phosphorylase [PNP] deficiency

Injury of muscle and tendon at hip and thigh level

11 (0.22)

Malignant neoplasm of breast, ER-positive, excluding all cancers (controls excluding all cancers)

52 (0.32)

-0.05 [-0.30, 0.20]

Diseases of tongue

12 (0.33)

Thalassaemia trait

0 (0.00)

Other benign neoplasm of uterus: Other parts/unspecified

7 (0.27)

Carcinoma in situ of lip, oral cavity and pharynx

0 (0.00)

COPD, hospital admissions

82 (0.34)

Other special examinations and investigations of persons without complaint or reported diagnosis

500 (0.32)

Open wound of wrist and hand

52 (0.22)

Burns and corrosions of multiple body regions

0 (0.00)

Chromomycosis and phaeomycotic abscess

0 (0.00)

Other abnormal immunological findings in serum

Other chorioretinal disorders in diseases classified elsewhere

0 (0.00)

Other specified disorders of eye and adnexa in diseases classified elsewhere

0 (0.00)

Findings of drugs and other substances, not normally found in blood

Pulmonary heart disease, diseases of pulmonary circulation

35 (0.22)

Carcinoma in situ of other/unspecified digestive organs

0 (0.00)

Disorders of pyruvate metabolism and gluconeogenesis

0 (0.00)

Ainhum

Effects of foreign body entering through natural orifice

36 (0.29)

Calcific aortic valvular stenosis, including rheumatic fever

36 (0.26)

Benign neoplasm: Kidney

8 (0.34)

Other and unspecified injuries of ankle and foot

6 (0.21)

Eosinophilic cellulitis [Wells]

0 (0.00)

Contact with blunt object, undetermined intent

Other haemoglobinopathies

0 (0.00)

-0.52 [-0.98, -0.06]

Granuloma faciale [eosinophilic granuloma of skin]

0 (0.00)

Myelodysplastic syndrome

0 (0.00)

Benign neoplasm of other and unspecified endocrine glands

20 (0.32)

malignant neoplasm of female genital organs

14 (0.20)

Disorders of sexual preference

0 (0.00)

0.24 [-0.22, 0.70]

Use of rivastigmine

20 (0.30)

Immunization not carried out

Phlebitis and thrombophlebitis of femoral vein, drug-induced

0 (0.00)

Nephropathy induced by heavy metals, drug-induced

Fenamates

34 (0.23)

Other cystitis, drug-induced

0 (0.00)

Malignant neoplasm of other and ill-defined digestive organs, excluding all cancers (controls excluding all cancers)

0 (0.00)

Direct fill therapy

18 (0.26)

Acute generalized exanthematous pustulosis

5 (0.18)

Benign neoplasm: Brain, supratentorial

Malignant neoplasm of rectosigmoid junction

0 (0.00)

Fetus and newborn affected by noxious influences transmitted via placenta or breast milk

Rhabdomyosarcoma, excluding all cancers (controls excluding all cancers)

0 (0.00)

-0.13 [-0.50, 0.24]

Secondary and unspecified malignant neoplasm of lymph nodes

6 (0.14)

Non-Hodgkin lymphoma, all, excluding all cancers (controls excluding all cancers)

30 (0.46)

0.25 [-0.26, 0.77]

Sequelae of injuries involving multiple and unspecified body regions

0 (0.00)

Immune checkpoint inhibitor medicines

Carcinoma in situ of other and unspecified sites

5 (0.21)

Paracoccidioidomycosis

0 (0.00)

Defects of catalase and peroxidase

0 (0.00)

Follicular adenocarcinoma of thyroid gland, excluding all cancers (controls excluding all cancers)

0 (0.00)

-0.13 [-0.82, 0.56]

Neonatal aspiration syndromes

Dyslexia and other symbolic dysfunctions, not elsewhere classified

0 (0.00)

Other and unspecified medical devices associated with adverse incidents

0 (0.00)

Unspecified severe protein-energy malnutrition

0.15 [-0.22, 0.53]

Use of galantamine

8 (0.21)

Secondary sideroblastic anaemia

0.13 [-0.31, 0.57]

Benign neoplasm: Liver/bile ducts (ICD-9)

Benign neoplasms

1168 (0.83)

Alcoholic cardiomyopathy

0 (0.00)

0.32 [-0.25, 0.90]

Dislocation, sprain and strain of joint and ligaments of hip

6 (0.24)

Disorders of aromatic amino-acid metabolism

0.04 [-0.47, 0.56]

Benign neoplasm: Uterine tubes and ligaments

0 (0.00)

Ototoxic hearing loss

0 (0.00)

-0.03 [-0.46, 0.39]

Primary_lymphoid and hematopoietic malignant neoplasms

43 (0.38)

0.32 [-0.20, 0.83]

Acute myeloid leukaemia and myelodysplastic syndromes, excluding all cancers (controls excluding all cancers)

0.39 [-0.45, 1.23]

Alkalosis

0 (0.00)

0.18 [-0.33, 0.69]

Malignant neoplasm of nasal cavity and middle ear, excluding all cancers (controls excluding all cancers)

Duodenal ulcer - Chronic or unspecified with perforation, drug-induced

Pedestrian injured in transport accident

Benign neoplasm: Cornea

9 (0.74)

Syndactyly

0 (0.00)

-0.14 [-0.56, 0.27]

Occupant of special vehicle mainly used on industrial premises injured in transport accident

Taeniasis

Alport

0 (0.00)

Other chondrocalcinosis

-0.52 [-1.12, 0.08]

Need for immunization against certain single viral diseases

Hypothyroidism, other/unspecified

190 (0.28)

Female infertility, uterine origin

0 (0.00)

-0.18 [-0.67, 0.30]

Use of eteplirsen

Left side

0 (0.00)

Polyarteritis with lung involvement [Churg-Strauss]/EGPA

0.21 [-0.27, 0.69]

Type 1 diabetes, wide definition, subgroup 1

20 (0.17)

Flexion deformity

Preparation and fitting of bite rail to mouth

13 (0.18)

Typhoid and paratyphoid fevers

0 (0.00)

0.06 [-0.58, 0.69]

Contact with other hot fluids

5 (0.22)

Benign neoplasm: Short bones of lower limb

Disseminated intravascular coagulation [defibrination syndrome]

0.10 [-0.46, 0.65]

Other congenital malformations of skull and face bones

0 (0.00)

0.21 [-0.27, 0.70]

Abnormal involuntary movements

18 (0.27)

Surgical ablation of atrial fibrillation

Glaucoma-related operations

11 (0.35)

Miliaria crystallina

0 (0.00)

Immunodeficiency following hereditary defective response to Epstein-Barr virus

0 (0.00)

Dietary calcium deficiency

0 (0.00)

Nondiabetic hypoglycaemic coma, drug-induced

Neuroendocrine tumor and carcinoma of rectum, excluding all cancers (controls excluding all cancers)

0 (0.00)

-0.07 [-0.53, 0.38]

Bacterial pneumonia (organism specified)

62 (0.26)

Other parasitologically confirmed or unspecified malaria

0 (0.00)

0.20 [-0.23, 0.64]

Systemic sclerosis, icd10

Hyperhidrosis

Carcinoma in situ of breast, other/unspecified

COPD, hospital admissions 1, only main diagnosis

52 (0.29)

Infliximab

Biliary cirrhosis, NAS

0 (0.00)

0.14 [-0.26, 0.55]

Benign neoplasm: Respiratory system, unspecified

0 (0.00)

0.22 [-0.25, 0.69]

Other disorders of skin and subcutaneous tissue in diseases classified elsewhere

L02BX Other hormone antagonists and related agents

8 (0.28)

Chronic lymphocytic leukaemia and small lyphocytis leukaemia, excluding all cancers (controls excluding all cancers)

-0.30 [-0.85, 0.25]

Use of safinamide

Amiodarone users

10 (0.20)

Heart failure,strict

104 (0.26)

L04AD Calcineurin inhibitors

17 (0.31)

Isolated proteinuria with specified morphological lesion

0 (0.00)

-0.47 [-1.24, 0.30]

Pseudofolliculitis barbae

0 (0.00)

Neurological devices associated with adverse incidents

0 (0.00)

Caught, crushed, jammed or pinched in or between objects

Malignant neoplasm of pyriform sinus

0 (0.00)

Folliculitis decalvans

0 (0.00)

0.37 [-0.06, 0.80]

Pemphigus vegetans

0 (0.00)

Benign neoplasm: Trachea

0 (0.00)

Nephrotic syndrome, drug-induced

0 (0.00)

Other congenital malformations of kidney

0 (0.00)

-0.23 [-0.87, 0.41]

Death from sequelae of obstetric causes

Symptoms and signs involving the circulatory and respiratory systems

467 (0.29)

Open wound of forearm

19 (0.38)

Bus occupant injured in other and unspecified transport accidents

Injury of nerves and spinal cord at thorax level

Serum neuropathy, drug-induced

Benign neoplasm: Conjunctiva

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

1. Apply sex-specific rule

2. Check conditions

3. Check pre-conditions, main-only, mode, registry filters

4. Check minimum number of events

5. Include endpoints

6. Filter based on genotype QC (FinnGen only)

Similar endpoints

Case counts by codes

Summary Statistics

-FinRegistry-

Key figures

-FinnGen-

Key figures

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS (R11)

Matched cohort

LabWAS

Mortality – FinRegistry

Association

Females

Males

Mortality risk

Relationships between endpoints